Deuterated forms and derivatives of volinanserin

Deuterated vorinanserin compounds address poor ADME properties by stabilizing plasma levels and reducing toxic metabolites, enhancing treatment efficacy and safety for conditions like psychosis and Parkinson's disease.

JP2024163142AInactive Publication Date: 2024-11-21TERRAN BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024147359
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-21
Filing Date
2024-08-29
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Many drugs suffer from poor absorption, distribution, metabolism, and excretion (ADME) properties, leading to rapid metabolism, formation of toxic metabolites, and increased treatment costs, which current strategies like cytochrome P450 inhibitors fail to address effectively.

Method used

Development of deuterated forms and derivatives of vorinanserin, including prodrugs, to slow metabolic rate and reduce toxic metabolite formation by replacing hydrogen atoms with deuterium, enhancing ADME properties.

Benefits of technology

The deuterated vorinanserin compounds improve drug efficacy, safety, and tolerability by stabilizing plasma levels and reducing adverse effects, making them suitable for treating conditions like psychosis, schizophrenia, and Parkinson's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163142000001
    Figure 2024163142000001
  • Figure 2024163142000002
    Figure 2024163142000002
  • Figure 2024163142000003
    Figure 2024163142000003
Patent Text Reader

Abstract

To provide deuterated forms and derivatives of volinanserin.SOLUTION: Deuterated forms of volinanserin according to structural formula (I) and their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and methods of treatment or prevention using these compounds or pharmaceutical compositions are described. The compounds are useful for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, Lewy body dementia, sleep disorder (including insomnia), agitation, mood disorder (including depression), thromboembolic disorder, autism, and attention deficit hyperactivity disorder.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit of U.S. Provisional Patent Application No. 62 / 784,056, filed December 21, 2018, the entire teachings of which are incorporated herein by reference. [Background technology]

[0002] 2. Background of the Invention Many current drugs suffer from poor absorption, distribution, metabolism and / or excretion (ADME) properties that prevent their more widespread use or limit their use in certain indications. Poor ADME properties are also a major reason for the lack of drug candidates in clinical trials. In some cases, formulation techniques and prodrug strategies can be used to improve certain ADME properties, but these approaches often fail to address the underlying ADME problems present in many drugs and drug candidates. One such problem is rapid metabolism, which causes some drugs to be eliminated from the body too quickly, otherwise they would be highly effective in treating diseases. A possible solution to rapid drug clearance is frequent dosing or high doses to achieve sufficiently high drug plasma levels. However, this creates several potential treatment problems, such as reduced patient compliance with the dosing regimen, more acute side effects at higher doses, and increased treatment costs. Rapidly metabolized drugs can also expose patients to undesirable toxic or reactive metabolites.

[0003] Another ADME limitation that affects many drugs is the formation of toxic or biologically reactive metabolites.As a result, some patients who receive the drug may experience toxicity, or the safe dosing of such drugs may be restricted so that patients receive suboptimal amounts of active agent.In certain cases, modifying dosing intervals and formulation techniques can help reduce clinical adverse effects, but the formation of such undesirable metabolites is often inherent to the metabolism of compounds.

[0004] In some selected cases, metabolic inhibitors are co-administered with drugs that are excreted too rapidly. This is the case for drugs of the protease inhibitor class used to treat HIV infection. The FDA recommends co-medicating these drugs with ritonavir, an inhibitor of cytochrome P450 enzyme 3A4 (CYP3A4), the enzyme typically involved in their metabolism (see Kempf, DJ, et al., Antimicrobial agents and chemotherapy, 1997, 41(3):654-60). However, ritonavir causes adverse effects and adds a pill burden to HIV patients who must already take a combination of different drugs. Similarly, quinidine, a CYP2D6 inhibitor, has been added to dextromethorphan to reduce the rapid CYP2D6 metabolism of dextromethorphan in the treatment of affective dysregulation. However, quinidine has undesirable side effects that severely limit its use in potential combination therapies (Wang, L., et al., Clinical Pharmacology and Therapeutics, 1994, 56(6 Pt 1):659-67 and (See FDA label for quinidine at www.accessdata.fda.gov.)

[0005] In general, combining drugs with cytochrome P450 inhibitors is not a satisfactory strategy for reducing drug clearance. Inhibition of CYP enzyme activity may affect the metabolism and clearance of other drugs metabolized by the enzyme. CYP inhibition may cause other drugs to accumulate in the body to toxic levels.

[0006] A potentially attractive strategy for improving the metabolic properties of drugs is deuterium modification. This approach seeks to slow down the CYP-mediated metabolism of drugs or reduce the formation of undesirable metabolites by replacing one or more hydrogen atoms with deuterium atoms. Deuterium is a safe, stable, non-radioactive isotope of hydrogen. Deuterium forms stronger bonds with carbon compared to hydrogen. When selected, the increased bond strength imparted by deuterium can positively affect the ADME properties of a drug, potentially improving its efficacy, safety, and / or tolerability. At the same time, since the size and shape of deuterium are essentially the same as hydrogen, the replacement of hydrogen with deuterium is not expected to affect the biochemical potency and selectivity of a drug compared to the original chemical entity containing only hydrogen. Over the past 35 years, the effect of deuterium substitution on metabolic rate has only been reported for a very small percentage of approved drugs (e.g., Blake, MI, et al., J See Pharm Sci, 1975, 64:367-91; Foster, AB, Adv Drug Res 1985, 14:1-40 ("Foster"); Kushner, DJ, et al., Can J Physiol Pharmacol 1999, 79-88; Fisher, MB, et al., Curr Opin Drug Discov Devel, 2006, 9:101-09 ("Fisher"). Results were variable and unpredictable. For some compounds, deuteration caused a decrease in metabolic clearance in vivo. For others, metabolism was unchanged. Still other compounds demonstrated increased metabolic clearance. The variability of deuterium effects has led experts to question and even dismiss deuterium modification as a viable drug design strategy for inhibiting deleterious metabolism. (See Foster at p. 35 and Fisher at p. 101.) [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Kempf, DJ, et al., Antimicrobial agents and chemotherapy, 1997, 41(3):654-60 [Non-Patent Document 2] Wang, L., et al., Clinical Pharmacology and Therapeutics, 1994, 56(6 Pt 1):659-67 [Non-Patent Document 3] FDA label for quinidine at www.accessdata.fda.gov [Non-Patent Document 4] Blake, MI, et al., J Pharm Sci, 1975, 64:367-91 [Non-Patent Document 5] Foster, AB, Adv Drug Res 1985, 14:1-40 [Non-Patent Document 6] Kushner, DJ, et al., Can J Physiol Pharmacol 1999, 79-88 [Non-Patent Document 7] Fisher, MB, et al., Curr Opin Drug Discov Devel, 2006, 9:101-09 Summary of the Invention [Means for solving the problem]

[0008] Summary of the Invention The present invention relates to deuterated forms and derivatives (including prodrugs) of borinancerin, and pharma- ceutically acceptable salts thereof. In one aspect, the present invention relates to a compound of structural formula (I): [ka] or a pharma- ceutically acceptable salt thereof,1 and R 2 is independently selected from -CH3, -CH2D, -CHD2, and -CD3; X is -OH or -F; Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each independently selected from hydrogen and deuterium; However, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 At least one of Y contains deuterium. 1a , Y 1b , Y 2a , and Y 2b are deuterium, Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 At least one of Y contains deuterium. 3a , Y 3b , Y 4a , and Y 4bare deuterium, Y 1a , Y 1b , Y 2a , Y 2b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 at least one of which contains deuterium].

[0009] The present invention also provides compositions comprising the compounds of the present invention, including pharmaceutical compositions comprising the compounds of the present invention or a pharma- ceutical acceptable salt thereof and a pharma- ceutical acceptable carrier. ... 2A The present invention provides the use of such compounds, salts and compositions in a method for treating diseases and conditions that are beneficially treated by administering vorinancerin or other drugs mediated by .ALPHA.-receptor inverse agonism or antagonism. Some exemplary embodiments include a method for treating or preventing a disease or condition selected from psychosis, schizophrenia (including chronic schizophrenia), schizoaffective disorder, Parkinson's disease (including Parkinson's disease psychosis), Lewy body dementia, sleep disorder (including insomnia), agitation, mood disorder (including depression), thromboembolic disorder, autism, attention deficit hyperactivity disorder, and any combination thereof, comprising administering to a subject in need thereof a pharmacologic acceptable compound, salt or composition of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] Detailed Description of the Invention Borinancerin, also known as (R)-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, is a highly selective 5-HT 2A Vorinancerin is a 5-HT receptor antagonist. 2A It is widely used in scientific research to investigate the function of receptors.

[0011] Vorinancerin is being investigated in clinical trials as a potential antipsychotic, antidepressant and treatment for insomnia, which mimics some of the behavioral symptoms of schizophrenia in humans. It is also active in animal models where it blocks NMDA glutamatergic channel receptors, an effect known to be associated with increased vasopressin levels. De Paulis T, Curr Opin Investig Drugs. 2001 Jan;2(1):123-32.

[0012] Despite the beneficial activities of vorinancerin, there is a continuing need for new compounds to treat the aforementioned diseases and conditions. definition

[0013] The term "treat" means to slow, inhibit, attenuate, reduce, arrest, or stabilize the onset or progression of a disease (e.g., a disease described in the present invention), reduce the severity of a disease, or ameliorate the symptoms associated with a disease.

[0014] "Disease" means any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.

[0015] As used herein, the term "subject" includes humans and non-human mammals. Non-limiting examples of non-human mammals include mice, rats, guinea pigs, rabbits, dogs, cats, monkeys, apes, pigs, cows, sheep, horses, etc.

[0016] The term "alkyl" refers to a monovalent saturated hydrocarbon group. a ~C bAn alkyl is an alkyl having a to b carbon atoms. For example, a C1-C6 alkyl is an alkyl having 1 to 6 carbon atoms. In some embodiments, the alkyl can be linear or branched. In some embodiments, the alkyl can be primary, secondary, or tertiary. Non-limiting examples of alkyl groups include methyl, ethyl, propyl, including n-propyl and isopropyl, butyl, including n-butyl, isobutyl, sec-butyl, and t-butyl, pentyl, including, for example, n-pentyl, isopentyl, and neopentyl, and hexyl, including, for example, n-hexyl and 2-methylpentyl. Non-limiting examples of primary alkyl groups include methyl, ethyl, n-propyl, n-butyl, n-pentyl, and n-hexyl. Non-limiting examples of secondary alkyl groups include isopropyl, sec-butyl, and 2-methylpentyl. Non-limiting examples of tertiary alkyl groups include t-butyl.

[0017] The term "alkenyl" refers to a monovalent unsaturated hydrocarbon group, where the unsaturation is represented by a double bond. A C2-C6 alkenyl is an alkenyl having 2 to 6 carbon atoms. The alkenyl may be straight-chained or branched. Examples of alkenyl groups include CH2=CH-(vinyl), CH2=C(CH3)-, CH2=CH-CH2-(allyl), CH3-CH=CH-CH2-(crotyl), CH3-CH=C(CH3)-, and CH3-CH=CH-CH(CH3)-CH2-. When stereoisomerism of the double bond is possible, the stereochemistry of the alkenyl may be (E), (Z), or a mixture thereof.

[0018] The term "alkynyl" refers to a monovalent unsaturated hydrocarbon group, where the unsaturation is represented by a triple bond. A C2-C6 alkynyl is an alkynyl having 2 to 6 carbon atoms. The alkynyl can be straight-chained or branched. Examples of alkynyl groups include HC≡C-, CH3-C≡C-, CH3-C≡C-CH2-, CH3-C≡C-CH2-CH2-, and CH3-C≡C-CH(CH3)-CH2-.

[0019] The compounds described herein may be pegylated. A "pegylated" compound refers to a compound having at least one poly(ethylene glycol) chain covalently attached thereto. For example, R 3 can be a poly(ethylene glycol) (PEG) group. Typically, poly(ethylene glycol) has multiple (e.g., n) repeating units. (For example, -O(CH2CH2O) where n is between 5 and 350) n H). Polyethylene glycol is not limited to any particular number of repeating units n or any particular molecular weight, so long as the resulting PEGylated compound (e.g., of structural formula (II) described herein) is suitable as a prodrug. For example, the PEG group can have a molecular weight of up to 25 kDa. For example, the PEG group can be a low molecular weight PEG (i.e., ≦12 kDa) having a molecular weight of, for example, between 300 Da and 12 kDa, between 1 kDa and 12 kDa, between 3 kDa and 12 kDa, or between 3 kDa and 8 KDa. In another example, the PEG group can be a high molecular weight PEG (i.e., >12 kDa) having a molecular weight of, for example, between 12 kDa and 25 kDa, or between 18 kDa and 22 kDa.

[0020] "Amino acid ester" refers to a derivative of an amino acid in which the carboxylic acid group has been converted to an ester. For example, amino acid esters include valine ester, leucine ester, isoleucine ester, alpha-t-butylglycine ester, dimethylglycine ester, and the like.

[0021] Suitable amino acids include, but are not limited to, histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), threonine (Thr), tryptophan (Trp), valine (Val), arginine (Arg), cysteine ​​(Cys), glutamine (Gln), glycine (Gly), proline (Pro), serine (Ser), tyrosine (Tyr), alanine (Ala), asparagine (Asn), aspartic acid (Asp), glutamic acid (Glu), and selenocysteine ​​(Sec).

[0022] It will be recognized that, depending on the origin of chemical materials used in synthesis, some variation in natural isotope abundance will occur in the synthesized compound.Therefore, preparations of borinancerin will naturally contain a small amount of deuterated isotopologues.Despite this variation, the concentration of naturally abundant stable hydrogen and carbon isotopes is small and insignificant compared to the stable isotope substitution degree of the compound of the present invention.See, for example, Wada, E., et al., Seikagaku, 1994, 66:15; Gannes, LZ, et al., Comp Biochem Physiol Mol Integr Physiol, 1998, 119:725.

[0023] In the compounds of the present invention, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is specifically designated as "H" or "hydrogen", it is understood that the position has hydrogen of its natural isotopic composition. However, in certain embodiments as described, when a position is specifically designated as "H" or "hydrogen", the position has at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% hydrogen. In some embodiments as described, when a position is specifically designated as "H" or "hydrogen", the position incorporates ≦20% deuterium, ≦10% deuterium, ≦5% deuterium, ≦4% deuterium, ≦3% deuterium, ≦2% deuterium, or ≦1% deuterium. Also, unless otherwise stated, when a position is specifically designated as "D" or "deuterium," the position is understood to have an abundance of deuterium that is at least 3340 times greater than the natural abundance of deuterium, which is 0.015% (i.e., at least 50.1% incorporation of deuterium).

[0024] The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope.

[0025] In other embodiments, compounds of the invention have an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

[0026] In some embodiments, in compounds of the invention, each designated deuterium atom has a deuterium incorporation of at least 52.5%.

[0027] In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 60% deuterium incorporation.

[0028] In some embodiments, in compounds of the invention, each designated deuterium atom has a deuterium incorporation of at least 67.5%.

[0029] In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 75% deuterium incorporation.

[0030] In some embodiments, in compounds of the invention, each designated deuterium atom has a deuterium incorporation of at least 82.5%.

[0031] In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 90% deuterium incorporation.

[0032] In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 95% deuterium incorporation.

[0033] In some embodiments, in compounds of the invention, each designated deuterium atom has a deuterium incorporation of at least 97.5%.

[0034] In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 99% deuterium incorporation.

[0035] In some embodiments, in compounds of the invention, each designated deuterium atom has a deuterium incorporation of at least 99.5%.

[0036] The term "isotopologue" refers to a molecule whose chemical structure differs from a species of the present invention only in its isotopic composition.

[0037] The term "compound", when referring to a compound of the invention, refers to a collection of molecules having the same chemical structure except for possible isotopic variations among the constituent atoms of the molecule. Thus, it will be apparent to one of skill in the art that a compound represented by a particular chemical structure contains molecules having deuterium at each of the positions designated as deuterium in the chemical structure, and may also contain isotopologues having hydrogen atoms at one or more of the deuterium positions designated in the structure. The relative amounts of such isotopologues in a compound of the invention will depend on the isotopic purity of the deuteration reagents used to make the compound, as well as the efficiency of deuterium incorporation in the various synthetic steps used to prepare the compound. will depend on a number of factors. In certain embodiments, the total relative amount of such isotopologues will be less than 49.9% of the compounds. In other embodiments, the total relative amount of such isotopologues will be less than 47.5%, less than 40%, less than 32.5%, less than 25%, less than 17.5%, less than 10%, less than 5%, less than 3%, less than 1%, or less than 0.5% of the compounds.

[0038] The present invention also provides salts (e.g., pharma- ceutically acceptable salts) of the compounds of the present invention. Unless otherwise specified, and not expressly stated, salts (e.g., pharma- ceutically acceptable salts) of the compounds described herein can be substituted for the compounds described herein (e.g., compounds of structural formula (I), (II)) in any embodiment or aspect thereof described herein.

[0039] The salts of the compounds of the present invention are formed between an acid and a basic group of the compound, such as an amino functional group, or between a base and an acidic group of the compound, such as a carboxyl functional group. According to one embodiment, the compound is a pharma-ceutically acceptable acid addition salt. In one embodiment, the acid addition salt may be a deuterated acid addition salt.

[0040] The term "pharmacologically acceptable" as used herein refers to a component that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and other mammals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit / risk ratio. A "pharmacologically acceptable salt" means any non-toxic salt that is capable of providing, directly or indirectly, a compound of the invention upon administration to a recipient. A "pharmacologically acceptable counterion" is an ionic portion of a salt that is not toxic when released from the salt upon administration to a recipient.

[0041] Acids commonly used to form pharma-ceutically acceptable salts include inorganic acids such as hydrogen disulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, and phosphoric acid, and organic acids such as para-toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, para-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, and acetic acid, and related inorganic and organic acids. Accordingly, such pharma- ceutically acceptable salts include, but are not limited to, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioxide, hexyne-1,6-dioxide, hexyne-2,6-dioxide, hexyne-1,7-dioxide, hexyne-2,7-dioxide, hexyne-2,8-dioxide, hexyne-3,8-dioxide, hexyne-4,8-dioxide, hexyne-5,8-dioxide, hexyne-6,8-dioxide, hexyne-7,8-dioxide, hexyne-8,8-dioxide, hexyne-9,8-dioxide, hexyne-10,8-dioxide, hexyne-11,8-dioxide, hexyne-12,8-dioxide, hexyne-13,8-dioxide, hexyne-14,8-dioxide, hexyne-15,8-dioxide, hexyne-16,8-dioxide, hexyne-17,8-dioxide, hexyne-18,8-dioxide, hexyne-19,8-dioxide, hexyne-20,8-dioxide, hexyne-21,8-dioxide, hexyne-22,8-dioxide, hexyne-23,8-dioxide, hexyne-24,8-dioxide, hexyne-25,8-dioxide, hexyne-26 The pharmaceutically acceptable acid addition salts include diacid salts, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, terephthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, β-hydroxybutyrates, glycolates, maleates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, mandelates and other salts. In one embodiment, the pharmaceutically acceptable acid addition salts include salts formed with mineral acids, such as hydrochloric acid and hydrobromic acid, and especially salts formed with organic acids, such as maleic acid. In one embodiment, the acids commonly used to form pharmaceutically acceptable salts include the inorganic acids listed above, in which at least one hydrogen is replaced with deuterium.

[0042] The compounds of the invention (e.g., compounds of formula I) may contain asymmetric carbon atoms, for example as a result of deuterium substitution or otherwise. Thus, the compounds of the invention may be asymmetric in that they are free of individual enantiomers. The compounds of the present invention can exist as either racemic mixtures or scalemic mixtures of different proportions of enantiomers, or as individual respective stereoisomers substantially free of other possible stereoisomers. The term "substantially free of other stereoisomers" as used herein means that there is less than 25% of other stereoisomers, preferably less than 10% of other stereoisomers, more preferably less than 5% of other stereoisomers, and most preferably less than 2% of other stereoisomers. Methods for obtaining or synthesizing individual enantiomers for a given compound are known in the art and can be applied to the final compound, or to starting materials or intermediates, where feasible.

[0043] Unless otherwise specified, when a disclosed compound is named or depicted by a structure without specifying stereochemistry, and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.

[0044] The term "stable compound," as used herein, refers to compounds that have sufficient stability to permit their manufacture and maintain their compound integrity for a period of time sufficient to be useful for the purposes detailed herein (e.g., formulation into a therapeutic product, intermediates for use in the production of therapeutic compounds, isolatable or storable intermediate compounds, treatment of a disease or condition responsive to a therapeutic agent).

[0045] "D" and "d" both refer to deuterium. "Stereoisomers" both refer to enantiomers and diastereomers. "tert" and "t-" refer to tertiary, respectively. "sec" or "s-" refer to secondary, respectively. "n-" refers to normal. "i-" refers to iso. "US" refers to United States.

[0046] "Deuterium substituted" refers to one or more hydrogen atoms being replaced with the corresponding number of deuterium atoms.

[0047] Throughout this specification, variables may be referred to generally (e.g., "each R") or specifically (e.g., R 1 , R 2 , R 3 etc.) Unless otherwise specified, when a variable is referred to generally, it is meant to include all specific embodiments of that particular variable. therapeutic compounds

[0048] In certain embodiments, the present invention provides compounds of structural formula (I) [ka] , [wherein, R 1 and R 2 is independently selected from: -CH3, -CH2D, -CHD2, and -CD3; X is -OH or -F; Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each independently selected from hydrogen and deuterium; However, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2At least one of the following is a deuterium atom: However, Y 1a , Y 1b , Y 2a , and Y 2b are deuterium, Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 At least one of the following is a deuterium atom: However, Y 3a , Y 3b , Y 4a , and Y 4b are deuterium, Y 1a , Y 1b , Y 2a , Y 2b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 at least one of which contains deuterium].

[0049] In a further embodiment, the present invention provides a compound comprising: 1 and R 2 is independently selected from -CH3, -CH2D, -CHD2, and -CD3; X is -OH or -F; and Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , and Y11 are each independently selected from hydrogen and deuterium, with the proviso that Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 wherein at least one of the following groups contains deuterium:

[0050] In a further embodiment, the present invention provides a compound of structural formula (II) (i.e., a prodrug of a compound of structural formula (I)) [ka] or a pharma- ceutically acceptable salt thereof, R 1 and R 2 is independently selected from -CH3, -CH2D, -CHD2, and -CD3; R 3 is -C(O)-C 1~21 Alkyl (e.g., C(O)-C 1~6 Alkyl, -C(O)-C 5~19 Alkyl, -C(O)-C 9~17 Alkyl, or -C(O)-C 15 Alkyl (i.e., palmitoyl), -C(O)-C 2~8 Alkenyl, C(O)-C 2~8 alkynyl, polyethylene glycol (PEG), or amino acid; Here, the amino acid is bonded to the R 3 by bonding to the oxygen to which the group is attached, thereby forming an amino acid ester; Y 1a , Y 1b , Y 2a , Y 2b, Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each independently selected from hydrogen and deuterium; However, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 In an aspect of this embodiment of the compound of structural formula (II), at least one of Y 1a , Y 1b , Y 2a , and Y 2b are deuterium, Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 It is further provided that at least one of comprises deuterium; However, Y 3a , Y 3b , Y 4a , and Y 4b are deuterium, Y 1a , Y 1b , Y 2a , Y 2b , Y 5 , Y 6 , Y7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 at least one of which contains deuterium].

[0051] In certain embodiments of a compound of Structural Formula (I) or a compound of Structural Formula (II), R 1 and R 2 is independently selected from -CH3 and -CD3. In an aspect of this embodiment, X, if present, is -OH. In any further or preceding aspect of this embodiment, Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 In any further or preceding aspect of this embodiment, Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 and each are hydrogen. In still a further aspect of this embodiment or any of the preceding aspects of this embodiment, Y 1a and Y 1b In still further aspects of this embodiment or any of the preceding aspects of this embodiment, Y 2a and Y 2b In still further aspects of this embodiment or any of the preceding aspects of this embodiment, Y 3a and Y 3b In still further aspects of this embodiment or any of the preceding aspects of this embodiment, Y 4a and Y 4b is the same.

[0052] In yet a further aspect of this embodiment, R 1 and R 2is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 1a and Y 1b are the same, and Y 2a and Y 2b are the same, and Y 3a and Y 3b are the same, and Y 4a and Y 4b are the same, and Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each hydrogen.

[0053] In yet a further aspect of this embodiment, R 1 and R 2 is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a , Y 1b , Y 2a and Y 2b are the same, and Y 3a and Y 3b In yet a further aspect of this embodiment, R 1 and R 2 is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a and Y 1b are the same, and Y 2a , Y 2b , Y 3a and Y 3bIn still further aspects of this embodiment or any of the preceding aspects of this embodiment, Y 2a and Y 2b is deuterium. In still further aspects of this embodiment or any of the previous aspects of this embodiment, any atom not designated as deuterium is present at its natural isotopic abundance.

[0054] In another embodiment of the compound of formula (I) or the compound of formula (II), Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 and each are hydrogen. In still a further aspect of this embodiment or any of the preceding aspects of this embodiment, Y 1a and Y 1b In yet further aspects of this embodiment or the previous aspects of this embodiment, In either case, Y 2a and Y 2b In still further aspects of this embodiment or any of the preceding aspects of this embodiment, Y 3a and Y 3b In yet a further aspect of this embodiment, R 1 and R 2 is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a , Y 1b , Y 2a and Y 2b are the same, and Y 3a and Y 3b In yet a further aspect of this embodiment, R 1 and R 2is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a and Y 1b are the same, and Y 2a , Y 2b , Y 3a and Y 3b In still further aspects of this embodiment or any of the preceding aspects of this embodiment, Y 2a and Y 2b is deuterium. In still further aspects of this embodiment or any of the previous aspects of this embodiment, any atom not designated as deuterium is present at its natural isotopic abundance.

[0055] In another embodiment of the compound of formula (I) or the compound of formula (II), Y 1a and Y 1b In yet a further aspect of this embodiment, Y 2a and Y 2b In still further aspects of this embodiment or any of the preceding aspects of this embodiment, Y 3a and Y 3b In yet a further aspect of this embodiment, R 1 and R 2 is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a , Y 1b , Y 2a and Y 2b are the same, and Y 3a and Y 3bIn yet a further aspect of this embodiment, R 1 and R 2 is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a and Y 1b are the same, and Y 2a , Y 2b , Y 3a and Y 3b In still further aspects of this embodiment or any of the preceding aspects of this embodiment, Y 2a and Y 2b is deuterium. In still further aspects of this embodiment or any of the previous aspects of this embodiment, any atom not designated as deuterium is present at its natural isotopic abundance.

[0056] In another embodiment of the compound of formula (I) or the compound of formula (II), Y 2a and Y 2b In yet a further aspect of this embodiment, Y 3a and Y 3b In yet a further aspect of this embodiment, R 1 and R 2 is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a , Y 1b , Y 2a and Y 2b are the same, and Y 3a and Y 3bIn yet a further aspect of this embodiment, R 1 and R 2 is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a and Y 1b are the same, and Y 2a , Y 2b , Y 3a and Y 3b In still further aspects of this embodiment or any of the preceding aspects of this embodiment, Y 2a and Y 2b is deuterium. In still further aspects of this embodiment or any of the previous aspects of this embodiment, any atom not designated as deuterium is present at its natural isotopic abundance.

[0057] In another embodiment of the compound of formula (I) or the compound of formula (II), Y 3a and Y 3b In yet a further aspect of this embodiment, R 1 and R 2 is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a , Y 1b , Y 2a and Y 2b are the same, and Y 3a and Y 3b In yet a further aspect of this embodiment, R 1 and R 2 are independently -CH3 and and -CD3, X, if present, is -OH, and Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a and Y 1b are the same, and Y 2a , Y 2b , Y 3a and Y 3b In still further aspects of this embodiment or any of the preceding aspects of this embodiment, Y 2a and Y 2b is deuterium. In still further aspects of this embodiment or any of the previous aspects of this embodiment, any atom not designated as deuterium is present at its natural isotopic abundance.

[0058] In another embodiment of the compound of structural formula (I) or the compound of structural formula (II), R 1 and R 2 is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a , Y 1b , Y 2a and Y 2b are the same, and Y 3a and Y 3b In yet a further aspect of this embodiment, Y 2a and Y 2b is deuterium. In still further aspects of this embodiment or any of the previous aspects of this embodiment, any atom not designated as deuterium is present at its natural isotopic abundance.

[0059] In another embodiment of the compound of structural formula (I) or the compound of structural formula (II), R 1 and R 2 is independently selected from -CH3 and -CD3; X, if present, is -OH; Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a and Y 1b are the same, and Y 2a , Y 2b , Y 3a and Y 3b In yet a further aspect of this embodiment, Y 2a and Y 2b is deuterium. In still further aspects of this embodiment or any of the previous aspects of this embodiment, any atom not designated as deuterium is present at its natural isotopic abundance.

[0060] In another embodiment of the compound of formula (I) or the compound of formula (II), Y 2a and Y 2b is deuterium. In yet a further aspect of this embodiment, any atom not designated as deuterium is present at its natural isotopic abundance.

[0061] In another embodiment of the compounds of structural formula (I) or compounds of structural formula (II), any atom not designated as deuterium is present at its natural isotopic abundance.

[0062] In some embodiments, the compound of structural formula (I) or structural formula (II) is selected from any one of the compounds set forth in Table 1 (below), where X, if present, is —OH and Y 1a and Y 1b are the same, and Y 2a and Y 2b are the same, and Y 3a and Y 3b are the same, and Y4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each hydrogen. [Table 1-1] [Table 1-2]

[0063] In some embodiments, the compound is selected from any one of the compounds set forth in Table 1 (above), where any atom not designated as deuterium is present at its natural isotopic abundance.

[0064] In some embodiments, the compound of structural formula (I) or structural formula (II) is selected from any one of the compounds set forth in Table 2 (below), where X, if present, is —OH and Y 1a and Y 1b are the same, and Y 2a and Y 2b are the same, and Y 3a and Y 3b are the same, and Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each hydrogen. [Table 2-1] [Table 2-2]

[0065] In some embodiments, the compound is selected from any one of the compounds set forth in Table 2 (above), where any atom not designated as deuterium is present at its natural isotopic abundance.

[0066] In some embodiments, the compound of structural formula (I) or structural formula (II) is selected from any one of the compounds set forth in Table 3 (below), where X is -OH and Y 1a and Y 1b are the same, and Y 2a and Y 2b are the same, and Y 3a and Y 3b are the same, and Y 4a and Y 4b are the same, and Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each hydrogen. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5]

[0067] In some embodiments, the compound is selected from any one of the compounds set forth in Table 3 (above), where any atom not designated as deuterium is present at its natural isotopic abundance.

[0068] In some embodiments, the compound of structural formula (I) or structural formula (II) is selected from any one of the compounds set forth in Table 4 (below), wherein X is -OH and Y 1a and Y1b are the same, and Y 2a and Y 2b are the same, and Y 3a and Y 3b are the same, and Y 4a and Y 4b are the same, and Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each hydrogen. [Table 4-1] [Table 4-2]

[0069] In some embodiments, the compound is selected from any one of the compounds set forth in Table 4 (above), where any atom not designated as deuterium is present at its natural isotopic abundance.

[0070] In some embodiments of the compounds of the present invention, Y 1a or Y 1b If is deuterium, then each Y designated as deuterium 1a or Y 1b The level of deuterium incorporation in the is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0071] In some embodiments of the compounds of the present invention, Y 2a or Y 2b If is deuterium, then each Y designated as deuterium 2a or Y 2b The level of deuterium incorporation in the is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0072] In some embodiments of the compounds of the present invention, Y3a or Y 3b If is deuterium, then each Y designated as deuterium 3a or Y 3b The level of deuterium incorporation in the is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0073] In some embodiments of the compounds of the present invention, Y 4a or Y 4b If is deuterium, then each Y designated as deuterium 4a or Y 4b The level of deuterium incorporation in the is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0074] In some embodiments of the compounds of the present invention, Y 5 If is deuterium, then each Y designated as deuterium 5 The level of deuterium incorporation in the is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0075] In some embodiments of the compounds of the present invention, Y 6 If is deuterium, then each Y designated as deuterium 6 The level of deuterium incorporation in the is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0076] In some embodiments of the compounds of the present invention, Y 7 If is deuterium, then each Y designated as deuterium 7 The level of deuterium incorporation in the is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0077] In some embodiments of the compounds of the present invention, Y 8 If is deuterium, then each Y designated as deuterium 8 The deuterium incorporation level in the At least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0078] In some embodiments of the compounds of the present invention, Y 9 If is deuterium, then each Y designated as deuterium 9 The level of deuterium incorporation in the is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0079] In some embodiments of the compounds of the present invention, Y 10 If is deuterium, then each Y designated as deuterium 10 The level of deuterium incorporation in the is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0080] In some embodiments of the compounds of the present invention, Y 11 If is deuterium, then each Y designated as deuterium 11 The level of deuterium incorporation in the is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0081] In some embodiments of the compounds of the invention, R 1 If -CH2D, -CHD2, or -CD3, R 1 The deuterium incorporation level at each designated deuterium is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0082] In some embodiments of the compounds of the invention, R 2 If -CH2D, -CHD2, or -CD3, R 2 The deuterium incorporation level at each designated deuterium is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0083] In another set of embodiments, any atom not designated as deuterium in any of the embodiments described herein is present at its natural isotopic abundance.

[0084] In some embodiments of the compounds of the invention, deuterium incorporation at each designated deuterium atom is at least 52.5%, at least 75%, at least 82.5%, at least 90%, at least 95%, at least 97%, or at least 99%.

[0085] In some embodiments of the compounds of the present invention, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 At least one of is hydrogen, and R 1 is -CH3, -CH2D or -CHD2, or R 2 is -CH3, -CH2D or -CHD2.

[0086] The synthesis of the compounds of formula (I) can be easily accomplished by a synthetic chemist of ordinary skill in the art by reference to the exemplary syntheses and examples disclosed herein. Related procedures similar to those used for the preparation of the compounds of formula (I) and their intermediates can be found, for example, in U.S. Patent Application Publication No. 2005 / 0,261,341; Huck, L., et. al., Org. Lett., 2017, 19, 3747-3750, Reddy,BP et al., WO2017017630A1, Winkler, M., et. al., Adv. Synth. Cat., 2007, 8+9, 1475-1480, Barker,O. et al., WO2012035023A1, Ratton,S. et al., EP0037353A1, Huet,L., et. al., Synlett, 2012, 23, 1230-1234, Senaweera,S., et. al., Chem. Comm., 2017, 53, 7545-7548, Shaik, S., et. al., Eur. J. Med. Chem., 2017, 126, 36-51, Mahtab, R., et. al., J. Chem. Phar m. Sci., 2014, 7, 34-38; Sakamuri, S., et. al., Bioorg. Med. Chem. Lett., 2001, 11, 495-500.

[0087] Such methods can be carried out by utilizing corresponding deuterated, and optionally other isotope-containing, reagents and / or intermediates to synthesize the compounds described herein, or by employing standard synthetic protocols known in the art for introducing isotopic atoms into a chemical structure.

[0088] Exemplary Synthesis A convenient method for synthesizing compounds of structural formula (I) is illustrated in Scheme 1. Scheme 1 [ka] [ka]

[0089] The synthesis of borinancerin (7a) was carried out according to the method described by Laux et al. in U.S. Patent Application Publication No. 2005 / 026. 1341 and begins with the conversion of carboxylic acid 1 to the corresponding Weinreb amide 2 via treatment with methoxymethylamine and CDI (carbonyldiimidazole). The reaction of 2 with Grignard reagent 3 generated from an aryl bromide then gives ketone 4. This can be done by reacting R 1 , R 2 , Y 7 , Y 8 and Y 9 This is a modification of the route described by Laux et al. to allow the preparation of Borinancerin analogues with asymmetric deuteration patterns at positions. Below is a full portio example illustrating the reaction of the proposed aryl Grignards with Weinreb amides as described in Huck, L., et. al., Org. Lett., 2017, 19, 3747-3750. [ka]

[0090] Removal of the Boc protecting group followed by reaction with alkyl bromide 9 (prepared in one step from primary alcohol 8 ) then affords ketone 6 , which is readily converted to borinaserin via asymmetric reduction using borane-dimethylsulfide in the presence of a chiral catalyst (( R )-methyl-CBS).

[0091] The final conversion process of intermediate 6 is 5 It can be used to obtain a high level of % D at position 1 (using K2CO3 / D2O or DCl) followed by a final asymmetric reduction. Alternatively, if a high level of % H is required at this stage, then Y 5It may be helpful to expose intermediate 6 to K2CO3 / H2O or HCl to completely de-enrich the site.

[0092] As shown above, the following synthetic intermediates and reagents are required to obtain the deuterated analogs presented in Scheme 1: 1, 3, 8, and BD3·SMe2. The reagent BD3·SMe2 is commercially available from Cambridge Isotope Laboratories, but obtaining the deuterated analogs of intermediates 1, 3, and 8 requires their individual synthetic preparation from commercially available deuterated precursors and reagents, as shown in Schemes 2–4 below.

[0093] Synthesis of analogues of all moieties of carboxylic acid 1 (1a, Y 3a =Y 3b =Y 4a =Y 4b =Y 5 =H) is shown in Scheme 2a below. The first step of the sequence involves the reduction of ketone 10a (commercially available from Sigma Aldrich) via treatment with sodium borohydride (NaBH4) according to the procedure described by Reddy et al. in WO2017 / 017630A1. The resulting alcohol 11a can then be converted to ketone 12a via the procedure reported in Winkler et al., Adv. Synth. Cat., 2007, 8+9,1475-1480. The nitrile 12a is then hydrolyzed to the carboxylic acid 1a via treatment with aqueous potassium hydroxide, following the procedure described by Barker et al. in WO 2012 / 035023 A1 for the hydrolysis of structurally similar compounds. 1b (Y 3a =Y 3b =Y 4a =Y 4b =H, Y 5=D) (Scheme 2b).

[0094] The remaining analogs (1c–1h) were commercially available as illustrated in Schemes 2c–2h below. can be similarly prepared starting from commercially available appropriately labeled starting materials (10b (99% D) available from CDN Isotopes, 10c (95-98% D) available from API Chemical, and 10d (98% D) available from CombiPhos).

[0095] By using appropriately deuterated reagents, Y 3a , Y 3b , Y 4a , Y 4b , and Y 5 Y of a compound of structural formula (I) (e.g., compound 7) or any suitable intermediate herein, for example, with about 90%, about 95%, about 97%, about 98% or about 99% deuterium incorporation. 3a , Y 3b , Y 4a , Y 4b , and Y 5 It is possible to incorporate deuterium at the position. Scheme 2. Synthesis of intermediates 1a-1h [ka] [ka] [ka]

[0096] Analogs of all moieties of aryl bromide 3 (3a, Y 7 =Y 8 =Y 9 =H;R 1 =R 2=CH3), commercially available from Alfa Aesar, its preparation according to literature procedures is shown in Scheme 3a. The first step of the sequence involves reacting catechol (13a, commercially available from Alfa Aesar) with methanol in the presence of sodium acetate and acetic acid to form the monomethyl ether 14a, as described by Ratton, S. et al., European Patent No. 0037353A1. The resulting phenol is then reacted with 14b to form the monomethyl ether 15a, as exemplified by Huet, L. et al., Synlett, 2012, 23, 1230-1234. The aryl group can be converted to 3a via a two-step process involving bromination followed by alkylation with methyl iodide.

[0097] The remaining analogs (3b-3h) can be prepared following the general route shown in Scheme 3a starting from either catechol (13a) or d4-catechol (13b (96% D), commercially available from Aldrich), using d4-methanol (99.8% D, commercially available from Aldrich) instead of methanol and / or d3-methyl iodide (99.5% D, commercially available from Aldrich) instead of methyl iodide as appropriate (Schemes 3b-3h).

[0098] By using appropriately deuterated reagents, Y 7 , Y 8 , Y 9 , R 1 , and R 2 Y of a compound of structural formula (I) (e.g., compound 7) or any suitable intermediate herein, for example, with about 90%, about 95%, about 97%, about 98% or about 99% deuterium incorporation. 7 , Y 8 , Y 9 , R 1 , and R 2 Incorporating deuterium into the position is possible. Scheme 3. Synthesis of intermediates 3a-3h [ka] [ka]

[0099] Analogs of all moieties of primary alcohol 8 (8a, Y 1a =Y 1b =Y 2a =Y 2b =Y 10 =Y 11 =H) is commercially available from Aldrich, but its preparation following literature procedures is shown in Scheme 4a. The first step in the sequence involves the reduction of 4-fluorobenzoic acid (16a, commercially available from Aldrich) with lithium aluminum hydride to give benzyl alcohol 17a, according to the method described by Shaik et. al., Chem. Comm., 2017, 53, 7545-7548. Subsequent treatment with phosphorous tribromide provided alkyl bromides 18a as described in (Eur. J. Med. Chem., 2017, 126, 36-51). Then, Mahtab et. al., J. Chem. Pharm. Sci., 2014, 7, 34-38 to the carboxylic acid 19a via a two-step procedure reported by Sakamuri et. al., Bioorg. Med. Chem. Lett., 2001, 11, 495-500. Finally, the primary alcohol 8a is obtained by reduction of the carboxylic acid 19a with borane according to the procedure of Sakamuri et. al., Bioorg. Med. Chem. Lett., 2001, 11, 495-500.

[0100] The remaining analogs (8b-8h) can be prepared following the general route shown in Scheme 4a starting from either 4-fluorobenzoic acid (16a) or d4-4-fluorobenzoic acid (16b (99% D), commercially available from CDN Isotope), using LiAlD4 (98% D, commercially available from Cambridge Isotope Laboratories) instead of LiAlH4 and / or BD3 (98% D, commercially available from Cambridge Isotope Laboratories) instead of BH3 as appropriate (Schemes 8b-8h).

[0101] By using appropriately deuterated reagents, Y 1a , Y 1b , Y 2a , Y 2b , Y 10 , and Y 11 In any of the above, for example, about 90%, about 95%, about 97%, about 98% or about 99% deuterium incorporation, Y 1a , Y 1b , Y 2a , Y 2b , Y 10 , and Y 11 It is possible to incorporate deuterium at the position. Scheme 4. Synthesis of intermediates 8a-8h [ka] [ka] [ka]

[0102] d 27 A proposed synthesis of -borinancerin (7h) is illustrated in Scheme 5 below as a representative example using the deuterated intermediates described herein. Scheme 5.d 27Representative synthesis of -borinancerin (7h) [ka] [ka]

[0103] By using appropriately deuterated reagents, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 , and / or R 2 In any of the above, for example, about 90%, about 95%, about 97% or about 99% deuterium incorporation, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 , and R 2 It is possible to incorporate deuterium at the position.

[0104] The specific procedures and compounds shown above are not intended to be limiting. The chemical structures in the schemes herein are represented by the same variable names (i.e., R 1 , R 2 , R 3Variables defined herein, whether or not identified by a group symbol (such as a hexadecimal number), are depicted according to the definition of the chemical group (moiety, atom, etc.) at the corresponding position in the formula of the compound herein. The suitability of a chemical group in a compound structure for use in the synthesis of another compound is within the knowledge of one of ordinary skill in the art.

[0105] Further methods of synthesizing the compounds of structural formula (I) and their synthetic precursors, including those in routes not explicitly shown in the schemes herein, are within the means of a chemist of ordinary skill in the art. The methods described herein may further include steps of adding or removing appropriate protecting groups to ultimately enable the synthesis of the compounds herein, either before or after the steps specifically described herein. Furthermore, the various synthetic steps may be performed in an alternative order or sequence to obtain the desired compounds. Synthetic chemical transformations and protecting group methodologies (protection and deprotection) useful in the synthesis of applicable compounds are known in the art and include, for example, Larock R, Comprehensive Organic Synthesis, Vol. 1, No. 1, pp. 111-115, 2002, and US Pat. No. 6,399,411. Transformations, VCH Publishers (1989), Greene, TW, et al., Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley and Sons (1999), Fieser, L., et al., Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994), and Paquette, L, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and This includes those found in subsequent editions of the

[0106] Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. composition

[0107] The invention also provides pharmaceutical compositions comprising an effective amount of a compound of structural formula (I) (e.g., of the first or second embodiment, or of any embodiment or aspect of an embodiment thereof described above) or structural formula (II), or a pharma- ceutically acceptable salt of said compound, and a pharma- ceutically acceptable carrier. The carrier is "acceptable" in the sense of being compatible with the other ingredients of the formulation and, in the case of a pharma- ceutically acceptable carrier, not deleterious to the recipient thereof in the amounts used in pharmaceuticals.

[0108] Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[0109] If necessary, the solubility and bioavailability of the compounds of the present invention in pharmaceutical compositions can be enhanced by methods well known in the art. One method involves using lipid excipients in the formulation. See "Oral Lipid-Based Formulations:Enhancing the Bioavailability of Poorly Water-Soluble Drugs (Drugs and the Pharmaceutical Sciences)," David J. Hauss, ed. Informa Healthcare, 2007 and "Role of the Compounds of the Invention," Drugs and the Pharmaceutical Sciences, ed., Drugs and the Pharmaceutical Sciences, 2009. of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery: Basic Principles and Biological Examples," Kishor M. Wasan, ed. Wiley-Interscience, 2006.

[0110] Another known method of enhancing bioavailability is the use of amorphous forms of the compounds of the invention, optionally formulated with poloxamers such as LUTROL® and PLURONIC® (BASF Corporation), or block copolymers of ethylene oxide and propylene oxide. See U.S. Patent No. 7,014,866 and U.S. Patent Application Publication Nos. 20060094744 and 20060079502.

[0111] Pharmaceutical compositions of the present invention include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. In certain embodiments, the compounds of the formulae herein are administered transdermally (e.g., using transdermal patches or iontophoretic technology). Other formulations can be conveniently presented in unit dosage form, e.g., tablets, sustained release capsules, and liposomes, and can be prepared by any method well known in the art of pharmacy. For example, see Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, Baltimore, MD (2013). h ed. 2000).

[0112] Such preparatory methods include the step of combining the molecule to be administered with ingredients such as the carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately combining the active ingredients with liquid carriers, liposomes or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0113] Another embodiment is a controlled release pharmaceutical composition comprising a compound of structural formula (I) (eg, of any embodiment or aspect of the embodiments described herein).

[0114] In one embodiment of the controlled release pharmaceutical composition, the controlled release pharmaceutical composition further comprises a release controlling agent and optionally a pharma- ceutically acceptable excipient.

[0115] The release controlling agent may be selected from a hydrophilic release controlling agent, a hydrophobic release controlling agent, or a mixture thereof.

[0116] The hydrophilic release controlling agent is selected from, but is not limited to, hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), polyethylene oxide, polyvinyl alcohol, polyvinylpyrrolidone, xanthan gum, guar gum, chitosan and its derivatives, carbomer, carrageenan, carboxymethyl cellulose, sodium alginate, polyglycolized glycerides, polyethylene glycol, or mixtures thereof.

[0117] Hydrophobic release controlling agents include, but are not limited to, polyvinyl acetate dispersions, ethyl cellulose, cellulose acetate, cellulose propionate (low, medium or high molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), and poly(hexyl methacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), waxes such as beeswax, camauba wax, para fin wax, microcrystalline wax, and ozokerite; fatty alcohols such as cetostearyl alcohol, stearyl alcohol, cetyl alcohol, and myristyl alcohol, and fatty acid esters such as glyceryl monostearate; glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl ester wax, glyceryl palmitostearate, glyceryl behenate, or hydrogenated vegetable oils.

[0118] The amount of release controlling agent may range from about 5% to about 95% by weight of the composition, more typically from about 25% to about 75% by weight of the composition, and more preferably from about 35% to about 65% by weight of the composition.

[0119] Pharmaceutically acceptable excipients include, but are not limited to, diluents, binders, solubilizers, solubility enhancers, pore-forming agents, osmagents, gas-forming agents, lubricants and glidants known to those skilled in the art.

[0120] Another embodiment comprises a compound of structural formula (I) (or any embodiment or aspect of an embodiment of a compound of structural formula (I)), a release controlling agent selected from a hydrophilic release controlling agent, a hydrophobic release controlling agent, and mixtures thereof, and optionally a pharma- ceutically acceptable excipient. , a controlled release pharmaceutical composition.

[0121] Another embodiment is a controlled release pharmaceutical composition comprising a compound of Structural Formula (I) (or any embodiment or aspect of an embodiment of a compound of Structural Formula (I)), a release controlling agent selected from a hydrophilic release controlling agent, a hydrophobic release controlling agent, and mixtures thereof, and optionally a pharma- ceutically acceptable excipient, wherein the hydrophilic release controlling agent is selected from hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), polyethylene oxide, polyvinyl alcohol, polyvinylpyrrolidone, xanthan gum, guar gum, chitosan and its derivatives, carbomer, carrageenan, carboxymethylcellulose, sodium alginate, polyglycolized glycerides, polyethylene glycol, and mixtures thereof.

[0122] Another embodiment is a controlled release pharmaceutical composition comprising a compound of structural formula (I) (or any embodiment or aspect of an embodiment of a compound of structural formula (I)), a release controlling agent selected from a hydrophilic release controlling agent, a hydrophobic release controlling agent, and mixtures thereof, and optionally a pharma- ceutically acceptable excipient, wherein the hydrophobic release controlling agent is selected from polyvinyl acetate dispersions, ethyl cellulose, cellulose acetate, cellulose propionate (low, medium or high molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), and poly(hexyl methacrylate), poly(butyl methacrylate), ... isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), waxes such as beeswax, carnauba wax, paraffin wax, microcrystalline wax, and ozokerite; fatty alcohols such as cetostearyl alcohol, stearyl alcohol, cetyl alcohol, and myristyl alcohol, and fatty acid esters such as glyceryl monostearate; glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl ester wax, glyceryl palmitostearate, glyceryl behenate, and hydrogenated vegetable oils.

[0123] U.S. Patent Application Publication No. 2013 / 0143897, published June 6, 2013, describes controlled release pharmaceutical compositions comprising blonanserin. In the described compositions, blonanserin can be substituted with a compound of structural formula (I) (or any embodiment or aspect of an embodiment of a compound of structural formula (I)) to form a controlled release pharmaceutical composition of the compound of the invention.

[0124] In certain embodiments, compound is administered orally.The composition of the present invention suitable for oral administration can be presented as separate units such as capsules, sachets or tablets, each containing a predetermined amount of active ingredient; powder or granules; solution or suspension in aqueous or non-aqueous liquid; oil-in-water liquid emulsion; water-in-oil liquid emulsion; filled in liposome; or bolus, etc.Soft gelatin capsules are useful for containing such suspensions, which can beneficially increase the absorption rate of compound.

[0125] For tablets for oral use, commonly used carriers include lactose and corn starch.Lubricants, such as magnesium stearate, are also typically added.For oral administration in capsule form, useful diluents include lactose and dried corn starch.When aqueous suspension is orally administered, active ingredient is combined with emulsifier and suspending agent.If desired, certain sweeteners and / or flavorings and / or colorings can be added.

[0126] Compositions suitable for oral administration include lozenges comprising the active ingredient in a flavored base, usually sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia.

[0127] Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain antioxidants, buffers, bacteriostatic agents, and solutes that make the preparation isotonic with the blood of the intended recipient, as well as aqueous and non-aqueous sterile suspensions that may contain suspending agents and thickening agents.The preparations may be presented in unit-dose or multi-dose containers, such as sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) state, requiring only the addition of a sterile liquid carrier for injection, such as water, immediately before use.Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.

[0128] Such injection solutions may be in the form of, for example, a sterile injectable aqueous or oleaginous suspension. The suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween® 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be used are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as a solvent or suspending medium. For this purpose, any non-irritating fixed oil may be used, including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives, are also useful in the preparation of injections, as are natural pharma-ceutically acceptable oils, such as olive oil or castor oil, especially their polyoxyethylated versions. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.

[0129] The pharmaceutical composition of the present invention can be administered in the form of suppositories for rectal administration.These compositions can be prepared by mixing the compound of the present invention with suitable non-irritating excipients that are solid at room temperature but become liquid at rectal temperature, and therefore melt in the rectum to release active ingredients.Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycol.

[0130] The pharmaceutical composition of the present invention can be administered by nasal aerosol or inhalation.Such compositions can be prepared according to the techniques well known in the pharmaceutical formulation field, and can be prepared as saline solution with benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other solubilizing or dispersing agents known in the art.See, for example, U.S. Patent No. 6,803,031 to Rabinowitz JD and Zaffaroni AC, assigned to Alexza Molecular Delivery Corporation.

[0131] Topical administration of the pharmaceutical composition of the present invention is particularly useful when the desired treatment involves areas or organs easily accessible by topical application. For topical application to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compounds, emulsifying wax, and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compounds suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, sorbitan monostearate ... The active ingredients include alcohol, 2-octyldodecanol, benzyl alcohol, and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topical transdermal patches and iontophoretic administration are also included in the present invention.

[0132] The application of the subject's treatment may be local, such as administered to the desired site. A variety of techniques can be used to provide the composition to the subject's desired site, such as injection, use of a catheter, trocar, squirt device, Pluronic® gel, stent, sustained drug release polymer or other device that provides internal access.

[0133] Thus, according to yet another embodiment, the compounds of the present invention can be incorporated into compositions for coating implantable medical devices, such as artificial joints, artificial valves, vascular grafts, stents, or catheters.Suitable coatings and the general preparation of coated implantable devices are known in the art and are exemplified in U.S. Patent Nos. 6,099,562, 5,886,026, and 5,304,121.The coating is typically a biocompatible polymeric material, such as hydrogel polymers, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.The coating can be further coated with a suitable topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids, or combinations thereof, if necessary, to impart controlled release characteristics to the composition.Coatings for invasive devices are included in the definition of pharmaceutically acceptable carrier, adjuvant, or vehicle, as the terms are used herein.

[0134] According to another embodiment, the present invention provides a method of coating an implantable medical device comprising the step of contacting said device with a coating composition as described above. It will be apparent to one skilled in the art that coating of the device occurs prior to implantation into a mammal.

[0135] According to another embodiment, the present invention provides a method of impregnating an implantable drug release device, including but not limited to biodegradable polymer capsules or bullets, non-degradable diffusible polymer capsules and biodegradable polymer wafers, comprising the step of contacting said drug release device with a compound or composition of the present invention.

[0136] According to another embodiment, the present invention provides an implantable medical device coated with a compound of the present invention or a composition comprising a compound, such that the compound of the present invention becomes therapeutically active.

[0137] According to another embodiment, the present invention provides an implantable medical device impregnated with or containing a compound of the present invention or a composition comprising a compound, such that the compound of the present invention is released from the device and becomes therapeutically active.

[0138] Where an organ or tissue is accessible by removal from a subject, such organ or tissue may be immersed in a medium containing the composition of the present invention, the composition of the present invention may be painted onto the organ, or the composition of the present invention may be applied in any other convenient manner.

[0139] In another embodiment, the composition of the invention further comprises one or more additional therapeutic agents, any compound known to have or that demonstrates advantageous properties when administered together with a compound having the same mechanism of action as vorinancerin. or therapeutic agents that have been shown to be useful in combination with vorinanserin, including, but not limited to, escitalopram.

[0140] Preferably, the additional therapeutic agent is an agent useful in the treatment of a disease or condition selected from psychosis, schizophrenia (including schizoprenia), schizoaffective disorder, Parkinson's disease (including Parkinson's disease psychosis), Lewy body dementia, sleep disorders (including insomnia), agitation, mood disorders (including depression), thromboembolic disorders, autism, and attention deficit hyperactivity disorder.

[0141] In one embodiment, the additional therapeutic agent is escitalopram.

[0142] In another embodiment, the present invention provides one or more separate dosage forms of the compound of the present invention and any of the above-mentioned additional therapeutic agents, wherein the compound and the additional therapeutic agent are associated with each other.The term "associated with each other" as used herein means that the separate dosage forms are packaged together or otherwise attached to each other, and therefore it is easily understood that the separate dosage forms are intended to be sold and administered together (within less than 24 hours of each other, consecutively or simultaneously).

[0143] In the pharmaceutical compositions of the present invention, the compounds of the present invention are present in an effective amount. As used herein, the term "effective amount" refers to an amount sufficient to treat the target disease when administered in a proper dosage regimen.

[0144] The term "subject in need thereof" refers to a subject having or diagnosed with a disease or condition selected from psychosis, schizophrenia (including chronic schizophrenia), schizoaffective disorder, Parkinson's disease (including Parkinson's disease psychosis), Lewy body dementia, sleep disorders (including insomnia), agitation, mood disorders (including depression), thromboembolic disorders, autism, and attention deficit hyperactivity disorder, or a subject at risk of suffering from or developing such a disease or disorder.

[0145] The interrelationship of dosages for animals and humans (based on milligrams per square meter of body surface) is described in Cancer Chemother. Rep, 1966, 50:219. Body surface area can be roughly determined from the subject's height and weight. See, for example, Scientific Tables, Geigy Pharmaceuticals, Ardsley, NY, 1970, 537.

[0146] In one embodiment, the effective amount of the compound of the present invention may range from 0.4 mg to 4 mg, 0.2 mg to 10 mg, or 0.02 mg to 20 mg. In a preferred embodiment, the effective amount is 2 mg.

[0147] In one embodiment, an effective amount of a compound of the invention can range from 0.4 mg / day to 4 mg / day, 0.2 mg / day to 10 mg / day, or 0.02 mg / day to 20 mg / day. In a preferred embodiment, the effective amount is 2 mg / day.

[0148] In one embodiment, the effective amount of the compound of the present invention may range from 0.008 mg / kg to 0.08 mg / kg, 0.004 mg / kg to 0.2 mg / kg, 0.0004 mg / kg to 0.4 mg / kg, In a preferred embodiment, the effective amount is 0.04 mg / kg.

[0149] In one embodiment, the effective amount of the compound of the present invention is from 0.008 mg / kg per day to 0.08 mg / kg per day, from 0.004 mg / kg per day to 0.2 mg / kg per day. The effective dose may range from 0.0004 mg / kg per day to 0.4 mg / kg per day, in a preferred embodiment, the effective dose is 0.04 mg / kg per day.

[0150] The effective amount can be administered once a day or twice a day, every two days, once a week or once every two weeks. In a preferred embodiment, the effective amount is administered once a day. As recognized by those skilled in the art, the effective dose also varies depending on the disease being treated, the severity of the disease, the route of administration, the sex, age and general health of the subject, the use of excipients, the possibility of co-use with other therapeutic treatments such as the use of other drugs, and the judgment of the treating physician. For example, the guideline for selecting the effective dose can be determined by referring to the prescription information for Vorinancerin.

[0151] For pharmaceutical compositions containing one or more additional therapeutic agents, the effective amount of the additional therapeutic agent is between about 20% and 100% of the dosage normally utilized in a monotherapy regimen using only that agent. Preferably, the effective amount is between about 70% and 100% of the normal monotherapy dose. The normal monotherapy dosages of these additional therapeutic agents are well known in the art. See, for example, Wells et al., eds., Pharmacotherapy Handbook, 2nd Edition, Appleton and Lange, Stamford, Conn. (2000), PDR Pharmacopoeia, Tarascon Pocket Book, 2000, each of which is incorporated herein by reference in its entirety. See Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000).

[0152] Some of the above-mentioned additional therapeutic agents can act synergistically with the compound of the present invention.When this occurs, the effective dosage of the additional therapeutic agent and / or the compound of the present invention can be reduced from the dosage required for monotherapy.This has the advantage of minimizing the toxic side effects of any of the additional therapeutic agents of the compound of the present invention, synergistically improving efficacy, improving ease of administration or use, and / or reducing the overall cost of preparing or formulating the compound.

[0153] Treatment

[0154] In another embodiment, the present invention provides a method for determining whether serotonin 5-HT is activated in cells. 2A Receiving Provided are methods of antagonizing or counter-stimulating the activity of a receptor, comprising contacting a cell with one or more compounds of structural formula (I) (e.g., of any embodiment or aspect of that embodiment) or structural formula (II), or a pharma- ceutically acceptable salt thereof. In some embodiments, the cell is contacted in vitro. In some embodiments, the cell is contacted in vivo. In some embodiments, the cell is contacted ex vivo.

[0155] In certain embodiments, the present invention provides a method for treating a disease that is beneficially treated by a compound of structural formula (I) in a subject in need thereof, comprising administering to the subject an effective amount of the compound, or a pharma- ceutically acceptable salt thereof, or a composition of the present invention (including pharmaceutical compositions and controlled release pharmaceutical compositions described herein).In certain embodiments, the subject is a patient in need of such treatment.In certain embodiments, the subject is a human being.

[0156] In a further embodiment, the present invention provides a pharmaceutical composition for treating or preventing a disease or condition selected from psychosis, chronic schizophrenia (including chronic schizophrenia), schizoaffective disorder, Parkinson's disease (including Parkinson's disease psychosis), dementia with Lewy bodies, sleep disorders (including insomnia), agitation, mood disorders (including depression), thromboembolic disorders, autism, attention deficit hyperactivity disorder, and any combination thereof, comprising a compound represented by structural formula (I) (e.g., as defined herein): or an aspect of that embodiment) or a compound of structural formula (II), or a pharma- ceutically acceptable salt thereof.

[0157] In further embodiments, the present invention provides a compound of structural formula (I) (e.g., of the embodiments or aspects of embodiments thereof described herein) or structural formula (II), or a pharma- ceutically acceptable salt thereof, for use in the treatment or prophylaxis of a disease or condition selected from psychosis, schizophrenia (including chronic schizophrenia), schizoaffective disorder, Parkinson's disease (including Parkinson's disease psychosis), Lewy body dementia, sleep disorders (including insomnia), agitation, mood disorders (including depression), thromboembolic disorders, autism, attention deficit hyperactivity disorder, and any combination thereof.

[0158] In a further embodiment, the invention provides the use of a compound of structural formula (I) (e.g., of the embodiments or aspects of embodiments thereof described herein) or structural formula (II), or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing a disease or condition selected from psychosis, schizophrenia (including chronic schizophrenia), schizoaffective disorder, Parkinson's disease (including Parkinson's disease psychosis), Lewy body dementia, sleep disorders (including insomnia), agitation, mood disorders (including depression), thromboembolic disorders, autism, attention deficit hyperactivity disorder, and any combination thereof.

[0159] Diseases amenable to the methods of treatment disclosed herein are well known in the art and include, but are not limited to, psychosis, schizophrenia (including chronic schizophrenia), schizoaffective disorder, Parkinson's disease (including Parkinson's psychosis), Lewy body dementia, sleep disorders (including insomnia), agitation, mood disorders (including depression), thromboembolic disorders, autism, and attention deficit hyperactivity disorder.

[0160] Identification of subjects in need of such treatment can be left to the judgment of the subject or a medical professional and can be subjective (eg, opinion) or objective (eg, measurable by a test or diagnostic method).

[0161] In another embodiment, any of the above treatment methods comprises the further step of co-administering one or more additional therapeutic agents to the subject in need thereof.The selection of additional therapeutic agents can be made from any additional therapeutic agent known to be useful for co-administration with Borinane Serrington.The selection of additional therapeutic agents also depends on the specific disease or condition being treated.The examples of additional therapeutic agents that can be used in the method of the present invention are those mentioned above for use in the combination composition that comprises the compound of the present invention and additional therapeutic agents.

[0162] In particular, the combination therapies of the present invention include co-administering to a subject in need thereof a compound of structural formula (I) (e.g., of the embodiments or aspects of embodiments thereof described herein) or structural formula (II), or a pharma- ceutically acceptable salt thereof, and one or more additional therapeutic agents, for the treatment of the following conditions (the specific additional therapeutic agents are indicated in parentheses after the indication): depression (escitalopram).

[0163] The term "co-administered" as used herein means that the additional therapeutic agent may be administered together with the compound of the invention as part of a single dosage form (e.g., a composition of the invention comprising a compound of the invention and the aforementioned additional therapeutic agent) or as separate multiple dosage forms. Alternatively, the additional agent may be administered prior to, sequentially with, or after administration of the compound of the invention. In such combination therapy treatments, the compound of the invention and the additional therapeutic agent are both administered by conventional methods. Administration of a composition of the invention comprising both a compound of the invention and an additional therapeutic agent to a subject does not necessarily necessitate separate administration of that very therapeutic agent, any other additional therapeutic agent, or any compound of the invention to said subject at different times during the course of treatment. This does not exclude that.

[0164] Effective amounts of these additional therapeutic agents will be known to those of skill in the art, and guidance for dosing can be found in the patents and published patent applications referenced herein, as well as in Wells et al., eds., Pharmacotherapy Handbook, 2nd Edition, Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000) and other medical textbooks. However, it is well within the purview of one of ordinary skill in the art to determine optimal effective amount ranges for additional therapeutic agents.

[0165] In one embodiment of the present invention, where an additional therapeutic agent is administered to a subject, the effective amount of the compound of the present invention is less than the effective amount when the additional therapeutic agent is not administered.In another embodiment, the effective amount of the additional therapeutic agent is less than the effective amount when the compound of the present invention is not administered.In this manner, the undesirable side effects associated with high doses of either agent can be minimized.Other potential advantages, including but not limited to improved dosing regimen and / or reduced drug cost, will be apparent to those skilled in the art.

[0166] In yet another aspect, the present invention provides the use of a compound of structural formula (I) (e.g., of the embodiments or aspects of the embodiments described herein) or structural formula (II), or a pharma- ceutically acceptable salt thereof, alone or together with one or more of the additional therapeutic agents described above, in the manufacture of a medicament, either as a single composition or in separate dosage forms, for the treatment of the aforementioned diseases, disorders, or symptoms in a subject. Another aspect of the present invention is a compound of structural formula (I) (e.g., of the embodiments or aspects of the embodiments described herein) or structural formula (II), or a pharma- ceutically acceptable salt thereof, for use in the treatment of a disease, disorder, or symptom thereof in a subject as described herein. EXAMPLES

[0167] Example 1 Synthesis of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanol (Compound 147) Scheme 6. Preparation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanol (compound 147). [ka] Step 1. 1,2-Bis(methoxy-d3)benzene (21b). To a solution of 1,2-dihydroxybenzene (20a) (30 g, 272.5 mmol) in anhydrous DMSO (250 mL) was added KOH (61.2 g, 1090 mmol) at room temperature followed by methyl iodide-d3 (42.4 mL, 681.1 mmol, Sigma Aldrich, >99.5% D atom). The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (800 mL) and extracted with CHCl (4×600 mL). The combined organic layers were washed with water (3×1 L), dried (NaSO), filtered and concentrated under reduced pressure. The residue was dried (vacuum oven) to give 21b (36.4 g, 92%) as a yellow oil.

[0168] Step 2. tert-Butyl 4-(2,3-bis(methoxy-d3)benzoyl)piperidine-1-carboxylate (4b). A solution of 2.5 M n-butyllithium in hexanes (50 mL, 125 mmol) was slowly added to a solution of 21b (18 g, 125 mmol) in THF (230 mL) at 0 °C. The reaction mixture was warmed to room temperature, stirred for 2 h, and then recooled to 0 °C. A solution of 2a (34.0 g, 125 mmol) in THF (400 mL) was precooled to 0 °C and slowly added to the reaction mixture. The reaction mixture was warmed to room temperature and stirred overnight. The reaction mixture was quenched with saturated aqueous NH4Cl (400 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 600 mL). The combined organic layers were washed with saturated brine (1 x 600 mL), dried (Na2SO4), filtered, and concentrated to a yellow oil. The crude material was purified in three batches by chromatography (Interchim automated chromatography system, SorbTech 330 g silica cartridge, eluting with a gradient of 5 to 20% EtOAc in hexanes) to give 4b (26.6 g, 60%) as a clear oil.

[0169] Step 3. (2,3-Bis(methoxy-d3)phenyl)(piperidin-4-yl)methanone (5b). A mixture of 4b (26.6 g, 75 mmol) and trifluoroacetic acid (172 mL, 2240 mmol) was stirred at room temperature for 30 min. The reaction mixture was concentrated under reduced pressure to give a clear oil. Et2O (800 mL) was added to the mixture to give a white precipitate. The precipitate was filtered to give 5b (26.5 g, 95%) as a white solid.

[0170] Step 4. (2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanone (6b). To a solution of 5b (5.0 g, 14.2 mmol) in anhydrous DMF (66 mL) at room temperature was added sodium bicarbonate (3.0 g, 35.5 mmol) followed by 9a (2.88 g, 14.2 mmol). The reaction mixture was heated at 90 °C for 3 h and then concentrated under reduced pressure. The residue was diluted with EtOAc (100 mL) and then washed with water (3 x 100 mL) and saturated brine (100 mL). The organic layer was concentrated under reduced pressure and the residue was purified by chromatography (Interchim automated chromatography system, Biotage Sfar 60 g silica cartridge, eluting with a gradient of 0-5% MeOH in CH2Cl2) to give 6b (2.96 g, 55%) as a brown oil.

[0171] Step 5. (2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanol (7b). Sodium borohydride (0.24 g, 6.37 mmol) was added to a solution of 6b (0.80 g, 2.12 mmol) in MeOH (30 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 h. The reaction mixture was cooled to 0 °C and sodium borohydride (0.16 g, 4.24 mmol) was added. The reaction mixture was warmed to room temperature and stirred for 16 h. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between water (50 mL) and EtOAc (50 mL). The layers were separated and the organic layer was extracted with EtOAc (2 x 50 mL). The combined organic layers were concentrated under reduced pressure and purified by chromatography (Interchim automated chromatography system, Interchim 25 g HP silica cartridge, eluting with a gradient of 0 to 10% MeOH in CH2Cl2) to give racemic 7b (0.51 g, 64%) as a white solid.

[0172] Chiral separation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanol (compound 147). 7b (0.44 g) was purified by chiral SFC (Chiralpak AD-H, 250×20 mm, 5 mm, 25% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 65 mL / min, wavelength 220 nm) to give the early eluting (R) enantiomer as a clear oil (220 mg).

[0173] The resulting clear oil was triturated with CH2Cl2 and hexanes to give compound 147 (212 mg, 96%) as a white solid.

[0174] 1 H NMR (400 MHz, CDCl3) δ 1.26-1.53 ​​(m, 3H), 1.68 (td , J = 3.9, 7.8, 11.6 Hz, 1 H), 1.81-2.02 (m, 2H), 2.04-2.11 (m, 1H), 2.39 (br s, 1H), 2.46 -2.58 (m, 2H), 2.70-2.82 (m, 2H), 2.92 (br d, J = 12.0 Hz, 1H), 3.07 (br d, J = 11.2 Hz, 1H), 4.63 (d, J = 8.1 Hz, 1H), 6.81-7.00 (m, 4H), 7.01 - 7.07 (m, 1H), 7.13 (t, J = 6.1 Hz, 2H).LCMS(Method:SorbTech C 18 AQ, 2.1×50mm, 3μ m, 5-95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, flow rate: 0.7 mL / min, wavelength: 210 nm): retention time: 4.7 min, 99.3% purity, (EI-MS): m / z = 380.2 ([M+H] + ).

[0175] Chiral HPLC (Chiralpak IG column, 150 mm x 4.6 mm, 3 μm, method: 100% EtOH, flow rate: 0.8 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 4.1 min, (S) isomer: 5.3 min, 99.9% ee.

[0176] Optical rotation [α] D 20 (2.14g / 100mL MeOH) = +19.1°. Example 2 Synthesis of (R)-(1-(4-fluorophenethyl)piperidin-4-yl)(2-methoxy-3-(methoxy-d3)phenyl)methanol (Compound 115). Scheme 7. Preparation of (R)-(1-(4-fluorophenethyl)piperidin-4-yl)(2-methoxy-3-(methoxy-d3)phenyl)methanol (compound 115). [ka]

[0177] Step 1. 2-((1-(4-fluorophenethyl)piperidin-4-yl)(hydroxy)methyl)-6-(methoxy-d3)phenol (30b). A solution of 1.0 M L-selectride in THF (27 mL, 27 mmol) was added to a solution of 6b (2.5 g, 7 mmol) in anhydrous THF (100 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h and then heated at 70 °C overnight. The reaction mixture was cooled to 0 °C and quenched with water (150 mL). The layers were separated and the aqueous layer was extracted with Et2O (2 x 150 mL). The combined organic layers were washed with saturated brine solution, dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by chromatography (Interchim automated chromatography system, Biotage 100 g silica cartridge, eluting with a gradient of 0-10% 0.3 M ammonia in MeOH in CH2Cl2) to give 30b (0.8 g, 33%) as a white solid.

[0178] Step 2. (1-(4-fluorophenethyl)piperidin-4-yl)(3-(methoxy-d3)-2-methoxyphenyl)-methanol (7c). Cesium carbonate (1.2 g, 3.8 mmol) was added to a solution of 30b (680 mg, 1.9 mmol) in acetone (60 mL) at room temperature. Methyl-4-methylbenzenesulfonate (321 mg, 1.7 mmol) was added in four portions over 4 h at room temperature. The reaction mixture was stirred at room temperature for 1 h, filtered through Celite (10 g), and the filter cake was washed with CHCl (2×50 mL). The filtrate was concentrated under reduced pressure. The residue was purified by chromatography (Interchim automated chromatography system, Biotage 55 g KP-NH cartridge, eluting with a gradient of 0–10% MeOH in CHCl). The resulting material was repurified as previously described to give racemic 7c (458 mg, 65%) as a clear oil.

[0179] Chiral separation of (R)-(1-(4-fluorophenethyl)piperidin-4-yl)(2-methoxy-3-(methoxy-d3)phenyl)methanol (compound 115). 7c (0.45 g) was purified by chiral SFC (AD-H, 250×20 mm, 5 mm, 25% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 60 mL / min, The early eluting (R) enantiomer was obtained as a clear oil (230 mg) at 220 nm wavelength. The resulting clear oil was triturated with CH2Cl2 and hexane to give compound 115 (184 mg) as a white solid.

[0180] 1 H NMR (400 MHz, CDCl3) δ 1.24 - 1.33 (m, 1H), 1.33 - 1.43 (m, 1H), 1.44 - 1.54 (m, 1H), 1.68 (tdt, J = 3.9, 7.8, 11.6 Hz, 1 H), 1.91 (dt, J = 2.8, 11.5 Hz, 1 H), 1.99 (dt, J = 2.4, 11.6 Hz, 1H), 2.05 - 2.11 (m, 1H), 2.37 (br s, 1H), 2.49 - 2.56 (m, 2H), 2.73 - 2.81 (m, 2H), 2.93 (br d, J = 10.9 Hz, 1H), 3.07 (br d, J = 11.2 Hz, 1H), 3.87 (s, 3H), 4.63 (d, J = 8.1 Hz, 1H), 6.84 (dd, J = 1.5, 8.1 Hz, 1H), 6.89 (dd, J = 1.5, 7.8 Hz, 1H), 6.91 - 6.98 (m, 2H), 7.02 - 7.08 (m, 1H), 7.10 - 7.16 (m, 2H).

[0181] LCMS (Method: Atlantis T3 column, 2.1 x 50 mm, 3 μm, 5 to 95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, Flow rate: 0.7 mL / min, Wavelength: 210 nm): Retention time: 4.5 min, 98.8% purity, (EI-MS): m / z = 377.2 ([M+H] + )

[0182] Chiral HPLC (Chiralpak IG column, 250 mm × 4.6 mm, 5 μm, method: 100% EtOH, flow rate: 1.0 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 4.8 min, (S) isomer: 5.8 min, 98.9% ee. Example 3 Synthesis of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methane-d-ol (Compound 148). Scheme 8. Preparation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methane-d-ol (compound 148). [ka]

[0183] Step 1. (2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methan-d-ol (7d). Sodium borodeuteride (0.64 g, 15.12 mmol, CIL, 99% D4) was added to a solution of 6b (1.90 g, 5.04 mmol) in MeOD (70 mL, Aldrich, 99.5% D atom) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 h. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between water (50 mL) and EtOAc (50 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2 x 50 mL). The combined organic layers were concentrated under reduced pressure to give 7d (2.4 g, quantitative) as a yellow oil.

[0184] Chiral separation. (R)-(2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methan-d-ol (compound 148). 7d (830 mg) was purified by chiral SFC (AD-H, 250×20 mm, 5 mm, 25% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 65 mL / min, wavelength 220 nm) to give the early eluting (R) enantiomer as a clear oil (398 mg).

[0185] The resulting clear oil was triturated with CH2Cl2 and hexanes to give compound 148 (286 mg) as a white solid.

[0186] 1 H NMR (400 MHz, CDCl3) δ 1.21-1.32 (m, 1H), 1.32-1.42 (m, 1H), 1.43-1.52 (m, 1H), 1.57 (s, 4H), 1.67 (tt, J = 3.8, 7.8, 11.6 Hz, 1H), 1.89 (dt, J = 2.9, 11.5 Hz, 1H), 1.97 (dt, J = 2.4, 11.7 Hz, 1H), 2.08 (br d, J = 13.1 Hz, 1H), 2.31 (br s, 1H), 2.49 - 2.54 (m, 2H), 2.73 - 2.78 (m, 2H), 2.92 (br d, J = 10.8 Hz, 1H), 3.07 (br d, J = 11.5 Hz, 1H), 3.81-3.85 (m, 1H), 4.60-4.65 (m, 1H), 6.84 (dd, J = 1.4, 8.1 Hz, 1H), 6.89 (dd, j = 1.5, 7.8 Hz, 1H), 6.95 (t, J = 8.7 Hz, 2H), 7.04 (t, J = 7.9 Hz, 1H), 7.13 (dd, J = 5.5, 8.5 Hz, 2H).

[0187] LCMS (Method: SorbTech C18AQ column, 2.1 × 50 mm, 3 μm, 5–95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, Flow rate: 0.7 mL / min, Wavelength: 210 nm): 4.6 min, 99.6% purity, (EI-MS): m / z = 381.3 ([M+H] + ).

[0188] Chiral HPLC (Chiralpak IG column, 150 mm × 4.6 mm, 3 μm, method: 100% EtOH, flow rate: 0.8 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 4.1 min, (S) isomer: 5.3 min, 99.7% ee. Example 4 Synthesis of (R)-(1-(4-fluorophenethyl)piperidin-4-yl)(3-methoxy-2-(methoxy-d3)phenyl)methanol (Compound 131) Scheme 9. Preparation of (R)-(1-(4-fluorophenethyl)piperidin-4-yl)(3-methoxy-2-(methoxy-d3)phenyl)methanol (compound 131). [ka]

[0189] Step 1. tert-Butyl 4-(2,3-bismethoxybenzoyl)piperidine-1-carboxylate (4a). A solution of 2.5 M n-butyllithium in hexanes (7.8 mL, 19.5 mmol) was added to a solution of 21a (2.7 g, 19.5 mmol) in anhydrous THF (30 mL) at 0 °C. The reaction mixture was warmed to room temperature for 2 h and then recooled to 0 °C. A precooled 0 °C solution of 2a (5.3 g, 19.5 mmol) in anhydrous THF (50 mL) was added slowly at 0 °C. The reaction mixture was warmed to room temperature and stirred overnight. The reaction mixture was quenched with saturated NH4Cl solution (100 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 120 mL). The combined organic layers were washed with saturated brine solution, dried (Na2SO4), filtered, and concentrated under reduced pressure. The residue was purified by chromatography (Interchim automated chromatography system, SorbTech220 silica cartridge, eluting with a gradient of 5 to 20% EtOAc in hexanes) to give 4a (4.05 g, 60%) as a clear oil.

[0190] Step 2. (2,3-Bismethoxyphenyl)(piperidin-4-yl)methanone trifluoroacetate (5a). Trifluoroacetic acid (44 mL, 576 mmol) was added to 4a (6.7 g, 19 mmol) at 0° C. The reaction mixture was stirred at room temperature for 30 min and then concentrated under reduced pressure to give a clear oil. Et2O (100 mL) was added and the mixture was stirred at room temperature for 2 h. The solid was filtered and washed with Et2O (50 mL) to give 5a (5.9 g, 90%) as a white solid.

[0191] Step 3. (2,3-Dimethoxyphenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanone (6a). NaHCO3 (3.6 g, 43 mmol) and 9a (3.5 g, 17 mmol) was added to a solution of 5a (5.9 g, 17 mmol) in DMF (80 mL) at room temperature. The reaction mixture was heated at 90° overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was adsorbed onto Celite (25 g) and then purified by chromatography (Interchim automated chromatography system, Biotage 100 g silica cartridge, eluting with a gradient of 0-10% MeOH in CH2Cl2) to give 6a (4.3 g, 68%) as a dark brown oil.

[0192] Step 4. 2-((1-(4-fluorophenethyl)piperidin-4-yl)(hydroxy)methyl)-6-methoxyphenol (30a). A solution of 1.0 L-selectride in THF (46 mL, 46 mmol) was added to a solution of 6a (4.3 g, 12 mmol) in anhydrous THF (200 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h and then heated at 70 °C overnight. The reaction mixture was cooled to 0 °C and diluted with water (150 mL). The layers were separated and the aqueous layer was extracted with Et2O (2 x 150 mL). The combined organic layers were washed with saturated brine solution and concentrated under reduced pressure. The residue was purified by chromatography (Interchim automated chromatography system, Biotage 100 g silica cartridge, eluting with a gradient of 0-10% 0.3 M ammonia / MeOH in CH2Cl2) to give 30a (2.9 g, 70%) as a yellow solid.

[0193] Step 5. (1-(4-fluorophenethyl)piperidin-4-yl)(3-methoxy-2-(methoxy-d3)phenyl)-methanol (7e). Cesium carbonate (564 mg, 1.7 mmol) was added to a solution of 30a (310 mg, 0.86 mmol) in acetone (50 mL) at room temperature. Methyl-d3-4-methylbenzenesulfonate (151 mg, 0.8 mmol, CDN, 99.5% D atom) was added to the reaction mixture at room temperature in four equal portions over 4 h. The reaction mixture was stirred at room temperature for 1 h, then filtered through Celite (10 g) and the filter cake was washed with CHCl (2×50 mL). The filtrate was concentrated under reduced pressure. The residue was purified by chromatography (Interchim automated chromatography system, Biotage 110 g KP-NH cartridge, eluting with a gradient of 0 to 10% MeOH in CH2Cl2) to give 7e (0.2 g, 62%) as a clear oil.

[0194] Chiral separation of (R)-(1-(4-fluorophenethyl)piperidin-4-yl)(3-methoxy-2-(methoxy-d3)phenyl)methanol (compound 131). 7e (390 mg) was purified by chiral SFC (AD-H, 250×20 mm, 5 mm, 25% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 60 mL / min, wavelength 220 nm) to give the early eluting (R) enantiomer as a clear oil (180 mg).

[0195] The resulting clear oil was triturated with CH2Cl2 and hexanes to give compound 131 (148 mg, 82% recovery) as a white solid.

[0196] 1 H NMR (400 MHz, CDCl3) δ 1.24 - 1.33 (m, 1H), 1.34 - 1.43 (m, 1H), 1.44 - 1.54 (m, 1H), 1.68 (tdt, J = 3.9, 7.8, 11.6 Hz, 1H), 1.79 (br s, 1H), 1.90 (dt, J = 2.9, 11.4 Hz, 1H), 1.98 (dt, J = 2.4, 11.7 Hz, 1H), 2.08 (quint, J = 2.8, 13.1 Hz, 1H), 2.37 (br s, 1H), 2.48 - 2.56 (m, 2H), 2.71 - 2.81 (m, 2H), 2.93 (br d, J = 11.1 Hz, 1H), 3.07 (br d, J = 11.4 Hz, 1H), 3.87 (s, 3H), 4.63 (d, J = 8.1 Hz, 1H), 6.84 (dd, J = 1.5, 8.2 Hz, 1H), 6.89 (dd, J = 1.5, 7.8 Hz, 1H), 6.91 - 6.98 (m, 2H), 7.01 - 7.07 (m, 1H), 7.10 - 7.17 (m, 2H).

[0197] LCMS (Method: Atlantis T3 column, 2.1 x 50 mm, 3 μm, 5 to 95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, Flow rate: 0.7 mL / min, Wavelength: 210 nm): Retention time: 4.6 min, 99.9% purity, (EI-MS): m / z = 377.2 ([M+H] + )

[0198] Chiral HPLC (Chiralpak IG column, 250 mm × 4.6 mm, 5 μm, method: 100% EtOH, flow rate: 1.0 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 4.8 min, (S) isomer: 5.8 min, 99.9% ee. Example 5 Synthesis of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl)methanol (Compound 151) Scheme 10. Preparation of 1-(2-bromoethyl-2,2-d2)-4-fluorobenzene (9b) [ka]

[0199] Step 1. 2-(4-Fluorophenyl)ethan-1,1-d2-1-ol (8b). 19a (5.0 g, 32.45 mmol) was dissolved in MeOD (8 mL, Cambridge Isotope, 99.8% D atom), concentrated under reduced pressure, then repeated twice. The residue was dissolved in anhydrous THF (20 mL) and added to a suspension of lithium aluminum deuteride (1.36 g, 32.45 mmol, Boc Sciences, 98% D atom) in anhydrous THF (50 mL) at 0 °C. The reaction mixture was warmed to room temperature, stirred for 1 h, then heated to reflux for 4 h. The reaction mixture was cooled to room temperature and quenched with water (1.5 mL), 15% sodium hydroxide solution (2 mL), then water (3 mL). The mixture was filtered through a Celite pad (20 g) and the filtrate was concentrated under reduced pressure. The crude product was purified by chromatography (Interchim automated chromatography system, RediSep 80 g silica cartridge, eluting with a 0-25% acetone in hexanes gradient) to give 8b (4.0 g, 87%) as a yellow oil.

[0200] Step 2. 1-(2-Bromoethyl-2,2-d2)-4-fluorobenzene (9b). Carbon tetrabromide (5.08 g, 15.32 mmol) was added to a solution of 8b (1.74 g, 12.26 mmol) in CHCl (25 mL) at 0 °C, followed by triphenylphosphine (4.82 g, 18.39 mmol). The reaction mixture was stirred at 0 °C for 1 h, then diluted with diethyl ether (100 mL) and hexanes (40 mL) and stirred for 40 min to form a white precipitate. The suspension was filtered through a Celite pad (20 g) to give a clear filtrate, which was concentrated under reduced pressure. The crude product was purified by chromatography (Interchim automated chromatography system, Biotage 100 g silica gel cartridge, eluting with a gradient of 0-10% EtOAc in hexanes) to give 9b (1.57 g, 63%) as a clear oil. Scheme 11. Preparation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl)methanol (compound 151). [ka]

[0201] Step 3. (2,3-Bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl)-methanone (6c). A solution of 9b (0.87 g, 4.24 mmol) in anhydrous DMF (1 mL) followed by sodium bicarbonate powder (0.89 g, 10.61 mmol) was added to a solution of 5b (1.5 g, 4.24 mmol) in anhydrous DMF (21 mL) at rt. The reaction mixture was heated at 90° C. for 3 h and then concentrated under reduced pressure. Water (30 mL) was added and the mixture was extracted with EtOAc (3×30 mL). The combined organic layers were washed with water (30 mL), saturated brine (30 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by chromatography (Interchim automated chromatography system, SorbTech 80 g silica gel cartridge, eluting with a gradient of 0 to 5% MeOH in CH2Cl2) to give 6c (0.58 g, 36%) as a yellow oil.

[0202] Step 4. (2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl)-methanol (7f). Sodium borohydride (0.173 g, 4.59 mmol) was added in one portion to a solution of 6c (0.58 g, 1.53 mmol) in MeOH (20 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between water (20 mL) and EtOAc (30 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2 x 30 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated under reduced pressure to give 7f (0.46 g, 80%) as a white solid.

[0203] Chiral separation. (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl)methanol (compound 151). 7f (437 mg) was purified by chiral SFC (AD-H, 250×20 mm, 5 mm, 25% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 60 mL / min, wavelength 220 nm) to give the early eluting (R) enantiomer as a clear oil (230 mg).

[0204] The resulting clear oil was triturated with CH2Cl2 and hexanes to give compound 151 (220 mg) as a white solid.

[0205] 1 H NMR (400 MHz, CDCl3) δ 1.22 - 1.34 (m, 2H), 1.38 (s, 1H), 1.48 (d, J = 24.5 Hz, 1H), 1.68 (d, J = 8.0 Hz, 1H), 1.89 (d, J = 20.3 Hz, 1H), 1.98 (d, J = 23.3 Hz, 1H), 2.08 (d, J = 18.5 Hz, 1H), 2.31 (s, 1H), 2.74 (s, 2H), 2.92 (d, J = 11.6 Hz, 1H), 3.06 (d, J = 11.9 Hz, 1H), 4.59 - 4.67 (m, 1H), 6.84 (d, J = 9.5 Hz, 1H), 6.89 (d, J = 8.9 Hz, 1H), 6.95 (t, J = 8.7 Hz, 2H), 7.04 (t, J = 7.9 Hz, 1H), 7.10 - 7.16 (m, 2H).

[0206] LCMS (Method: SorbTech C18AQ column, 2.1 x 50 mm, 3 μm, 5 to 95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, Flow rate: 0.7 mL / min, Wavelength: 210 nm): Retention time: 4.6 min, 98.6% purity, (EI-MS): m / z = 382.2 ([M+H] + )

[0207] Chiral HPLC (Chiralpak IG column, 150 mm x 4.6 mm, 3 μm, method: 100% EtOH, flow rate: 0.3 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 10.9 min, (S) isomer: 14.2 min, 99.7%ee Example 6 Synthesis of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1,2,2-d4)piperidin-4-yl)methanol (Compound 159) Scheme 12. Preparation of 1-(2-bromoethyl-1,1,2,2-d4)-4-fluorobenzene (9c) [ka]

[0208] Step 1. Methyl 2-(4-fluorophenyl)acetate-d2 (20b). A freshly prepared solution of 2.11 M sodium methoxide in MeOD (2.82 mL, 5.9 mmol) was added to a solution of 20a (10 g, 59.5 mmol) in MeOD (100 mL) at room temperature. The reaction mixture was stirred at room temperature overnight and then concentrated under reduced pressure to give a white semi-solid. Additional MeOD (110 mL) and a freshly prepared solution of 2.11 M sodium methoxide in MeOD (2.82 mL, 5.9 mmol) were added at room temperature and then the reaction mixture was stirred overnight. This process was repeated for a total of four cycles. The reaction mixture was concentrated under reduced pressure to give 20b (11.50 g, quantitative yield).

[0209] Step 2. 2-(4-Fluorophenyl)ethan-1,1,2,2-d4-1-ol (8c). A suspension of 20b (10 g, 58.7 mmol) in anhydrous THF (50 mL) was slowly added to a suspension of lithium aluminum deuteride (3.69 g, 88.0 mmol, Boc Sciences, 98% D atom) in anhydrous THF (100 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h, then heated to reflux for 4 h. The reaction mixture was cooled to room temperature and then quenched with water (3 mL), 15% NaOH solution (4 mL), then water (6 mL). The mixture became very thick during the quench, so THF was added as needed. The mixture was then filtered through a pad of Celite (20 g) and the filtrate was concentrated under reduced pressure. The crude product was purified by chromatography (Interchim automated chromatography system, Biotage 350 g silica gel cartridge, eluting with a gradient of 0 to 25% acetone in hexanes) to give 8c (7.06 g, 83%) as a clear oil.

[0210] Step 3. 1-(2-Bromoethyl-1,1,2,2-d4)-4-fluorobenzene (9c). Carbon tetrabromide (23.95 g, 72.0 mmol) was added to a solution of 8c (8.33 g, 58.0 mmol) in CHCl (140 mL) at 0 °C, followed by triphenylphosphine (22.73 g, 86.6 mmol). The reaction mixture was stirred at 0 °C for 2 h and then concentrated under reduced pressure to a yellow oil. The oil was diluted with EtO (400 mL) and stirred for 40 min to give a white suspension. The suspension was filtered through a Celite pad (20 g) to give a clear filtrate, which was concentrated under reduced pressure. Hexanes (300 mL) were added and the mixture was stirred for 15 min to give an additional white precipitate. The precipitate was filtered through a fine fritted funnel and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography (Biotage automated chromatography system, Biotage 350 g silica gel cartridge, eluting with a gradient of 0 to 25% EtOAc in hexanes) to give 9c (7.7 g, 64%) as a clear oil. Scheme 13. Preparation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1,2,2-d4)piperidin-4-yl)methanol (Compound 159) [ka]

[0211] Step 4. (2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1,2,2-d4)piperidin-4-yl)methanone (6d). A solution of 9c (0.70 g, 3.35 mmol, 1 equiv) in DMF (3 mL) followed by powdered sodium bicarbonate (0.71 g, 8.4 mmol) was added to a solution of 5b (1.2 g, 3.35 mmol) in DMF (15 mL) at rt. The reaction mixture was heated at 90 °C for 2 h, then cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (35 mL) and extracted with EtOAc (3 x 35 mL). The combined organic layers were washed with saturated brine (50 mL), water (30 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by chromatography (Biotage automated chromatography system, Biotage 50 g silica gel cartridge, eluting with a gradient of 0 to 5% MeOH in CH2Cl2) to give 6d (0.86 g, 68%) as a yellow oil.

[0212] Step 5. (2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1,2,2-d4)piperidin-4-yl)methanol (7g). Sodium borohydride (0.26g, 6.80mmol, 3eq) was added in one portion to a solution of 6d (0.86g, 2.27mmol, 1eq) in MeOH (30mL) at 0°C. The reaction mixture was warmed to room temperature and stirred for 38h. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between water (30mL) and EtOAc (30mL). The layers were separated and the aqueous layer was extracted with EtOAc (2x30mL). The combined organic layers were dried (Na2SO4), filtered and concentrated under reduced pressure to give 7g (0.77g, 89%) as a white solid.

[0213] Chiral separation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1,2,2-d4)piperidin-4-yl)methanol (compound 159). 7 g (700 mg) was purified by chiral SFC (AD-H, 250 x 20 mm, 5 mm, 25% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 65 mL / min, wavelength 220 nm) to give the early eluting (R) enantiomer as a clear oil (385 mg).

[0214] The resulting clear oil was triturated with CH2Cl2 and hexanes to give compound 159 (270 mg) as a white solid.

[0215] 1 H NMR (400 MHz, CDCl3) δ 1.21 - 1.42 (m, 2H), 1.42-1.55 (m, 1H), 1.68 (dtd, J = 4.0, 7.8, 11.6 Hz) (s, 2H), 1.91 (br t, J= 11.0 Hz, 1H), 1.99 (br t, J= 11.4 Hz, 1H), 2.08 (d, J = 2.7, 13.1 Hz, 1H), 2.35 (br s, 1H), 2.93 (d, J = 10.9 Hz, 1H), 3.07 (d, J = 10.8 Hz, 1H), 4.63 (d, J = 8.1 Hz, 1H), 6.84 (dd, J = 1.6, 8.1 Hz, 1H), 6.89 (dd, J = 1.4, 7.8 Hz, 1H), 6.91-6.98 (m, 2H), 7.02 - 7.07 (m, 1H), 7.10 - 7.17 (m, 2H).

[0216] LCMS (Method: Atlantis T3 column, 2.1 x 50 mm, 3 μm, 5 to 95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, Flow rate: 0.7 mL / min, Wavelength: 210 nm): Retention time: 4.5 min, 99.9% purity, (EI-MS): m / z = 384.3 ([M+H] + )

[0217] Chiral HPLC (Chiralpak IG column, 250 mm × 4.6 mm, 3 μm, method: 100% EtOH, flow rate: 0.3 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 16.9 min, (S) isomer: 21.5 min, 99.7% ee. Example 7 Synthesis of (R)-(2,3-dimethoxyphenyl)(1-(4-fluorophenethyl)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (Compound 203) Scheme 14. Preparation of tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate-2,2,3,3,4,5,5,6,6-d9 (2b). [ka]

[0218] Step 1. 1-(tert-Butoxycarbonyl)piperidine-4-carboxylic acid-2,2,3,3,4,5,5,6,6-d9 acid (1h). MeOD (12 mL, Sigma Aldrich, 99.5% D atom) was added to piperidine-4-carboxylic acid-2,2,3,3,4,5,5,6,6-d9 acid (3 g, CDN isotope, 98.6% D atom). The mixture was concentrated under reduced pressure. This process was repeated two more times. Next, triethylamine (6.6 g, 65.0 mmol) was added to a solution of piperidine-4-carboxylic acid-2,2,3,3,4,5,5,6,6-d9 acid (3 g, 22.0 mmol) in anhydrous CHCl (30 mL) followed by Boc anhydride (5.7 g, 26 mmol) at room temperature. The reaction mixture was stirred at this temperature overnight. The reaction mixture was concentrated under reduced pressure. THF (40 mL) was added to the residue and the mixture was acidified with 1N deuterium chloride (aq) (30 mL, Sigma, >99% D atom). The mixture was stirred for 15 min, then EtOAc (70 mL) was added. The layers were separated and the aqueous layer was extracted with EtOAc (2 x 70 mL). The organic layers were combined, washed with saturated brine in deuterium oxide (1 x 70 mL), dried (Na2SO4), filtered, concentrated under reduced pressure, and dried (vacuum oven) to give 1h (4.81 g, 93%).

[0219] Step 2. tert-Butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate-2,2,3,3,4,5,5,6,6-d9 (2b). Triethylamine (3.1 mL, 22.0 mmol) was added to solid N,O-dimethylhydroxylamine hydrochloride (2.14 g, 22.0 mmol) at room temperature and the mixture was stirred for 1 h to give the free-based N,O-dimethylhydroxylamine as an oil. DBU (3.38 g, 22.0 mmol) was added followed by propanephosphonic anhydride (1.07 g, 64.5 mmol) to a solution of 1h (4.81 g, 20.16 mmol) in anhydrous acetonitrile (60 mL) at 0 °C. After stirring for 15 min, the free-based N,O-dimethylhydroxylamine was added to the previous reaction mixture at 0 °C and stirred at this temperature for 3 h. The reaction mixture was then concentrated under reduced pressure. EtOAc (400 mL) was added to the residue and the mixture was washed with 25% citric acid (aq) (2×200 mL) and saturated sodium bicarbonate (2×200 mL). The organic layer was dried (Na2SO4), filtered and concentrated under reduced pressure to give 2b (3.31 g, 58%) as a yellow oil. Scheme 15. Preparation of (R)-(2,3-dimethoxyphenyl)(1-(4-fluorophenethyl)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (compound 203). [ka]

[0220] Step 1. tert-Butyl 4-(2,3-dimethoxybenzoyl)piperidine-1-carboxylate-2,2,3,3,4,5,5,6,6-d9 (4c). 2.5 M n-Butyllithium in hexane (1.95 mL, 4.86 mmol) A solution of was added dropwise to a solution of 21a (0.64 g, 4.6 mmol, 1 equiv) in anhydrous THF (11 mL) at 0° C. After the addition, the mixture was warmed to room temperature, stirred for 2 h, and then recooled to 0° C. A pre-cooled (0° C.) solution of 2b (1.30 g, 4.6 mmol) in anhydrous THF (9 mL) was added slowly to the reaction mixture. The reaction mixture was warmed to room temperature and stirred overnight. An additional portion of 21a (0.64 g, 4.6 mmol) in anhydrous THF (11 mL) was treated with 2.5 M n-BuLi in hexanes (1.95 mL, 4.86 mmol) at 0° C. and then added to the reaction mixture at 0° C. The reaction mixture was warmed to room temperature and stirred overnight. The reaction mixture was quenched with a saturated solution of ND4Cl in deuterium oxide (25 mL, CIL, 99.9% D atom) and stirred for 15 min. The layers were separated and the aqueous layer was extracted with Et2O (3 x 30 mL). The combined organic layers were washed with saturated brine in deuterium oxide (50 mL), dried (Na2SO4), filtered and concentrated under reduced pressure to give crude 4c (2.9 g) as a yellow oil. The crude material was purified by chromatography (Biotage automated chromatography system, Biotage 100 g silica gel cartridge, eluting with a gradient of 10-15% EtOAc in hexanes) followed by reverse phase chromatography (Biotage automated chromatography system, Teledyne 100 g C 18Purification by HPLC on a 500 rpm cartridge, eluting with 0-85% acetonitrile in water) gave 4c (0.51 g, 31%) with 22% proton incorporation alpha to the ketone. Potassium carbonate (0.3 g, 2.15 mmol) was added to a solution of the resulting 4c (0.51 g, 1.43 mmol) in a 1:1 mixture of deuterium oxide (50 mL, CIL, 99.9% D atom) and anhydrous THF (50 mL) at room temperature. The reaction mixture was stirred for 3 days. The reaction mixture was diluted with saturated brine in deuterium oxide (20 mL, CIL, 99.9% D atom) and then extracted with CHCl (150 mL). The aqueous layer was extracted with CHCl (50 mL). The combined organic layers were washed with saturated brine in deuterium oxide (20 mL), dried (NaSO), filtered, and concentrated under reduced pressure to give 4c (0.51 g).

[0221] Step 2. (2,3-Dimethoxyphenyl)(piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanone trifluoroacetate (5c). Trifluoroacetic acid-d (7.54 g, 66.11 mmol, Sigma Aldrich, 99.5% D atom) was added to 4c (0.79 g, 2.20 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1.5 h. The reaction mixture was concentrated under reduced pressure to give a yellow oil. Et2O (150 mL) was added and the mixture was stirred for 10 min to give a white precipitate. The solid was filtered to give 5c (0.66 g, 85%) as a white solid.

[0222] Step 3. (2,3-Dimethoxyphenyl)(piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (30b). Sodium borohydride (0.28 g, 7.45 mmol) was added in one portion to a solution of 5c (0.66 g, 1.86 mmol) in MeOD (35 mL, Sigma Aldrich, 99.5% D atom) at 0 °C. The reaction mixture was warmed to rt and stirred overnight. The reaction mixture was concentrated under reduced pressure, then the residue was partitioned between saturated sodium bicarbonate in deuterium oxide (60 mL, CIL, 99.9% D atom) and 10% MeOH in CHCl (100 mL). The layers were separated and the aqueous layer was extracted with 10% MeOH in CHCl (2 x 100 mL). The combined organic layers were washed with deuterium oxide (50 mL, CIL, 99.9% D atom), dried (Na2SO4), filtered, and concentrated under reduced pressure to give 30b (0.17 g). The combined aqueous layers were concentrated under reduced pressure, and the residue was extracted with CH2Cl2 (3 x 100 mL). The combined organic layers were concentrated under reduced pressure to give the total of 30b (0.40 g, 83%).

[0223] Step 4. (2,3-Dimethoxyphenyl)(1-(4-fluorophenethyl)piperidine Lysine-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (7j). A solution of 9a (0.15 g, 0.77 mmol) in anhydrous DMF (3 mL) followed by sodium bicarbonate powder (0.13 g, 1.54 mmol) was added to a solution of 30b (0.2 g, 0.77 mmol) in anhydrous DMF (7 mL) at rt. The reaction mixture was heated at 90° C. for 2 h and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure. The residue was diluted with water (10 mL) and extracted with EtOAc (3×25 mL). The combined organic layers were washed with saturated brine (20 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure to give 7j (0.26 g, 88%) as a yellow oil that solidified on standing.

[0224] Chiral separation. (R)-(2,3-dimethoxyphenyl)(1-(4-fluorophenethyl)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (compound 203). 7j (260 mg) was purified by chiral SFC (AD-H, 250×20 mm, 5 mm, 20% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 60 mL / min, wavelength 220 nm) to give the early eluting (R) enantiomer as a clear oil (130 mg).

[0225] The resulting clear oil was triturated with CH2Cl2 and hexanes to give compound 203 (86 mg) as a white solid.

[0226] 1 H NMR (400 MHz, CDCl3) δ 2.35 (bs, 1H), 2.49 - 2.55 (m, 2H), 2.72 - 2.83 (m, 2H), 3.87 (s, 6H), 4.63 (s, 1H), 6.85 (d, J = 8.1 Hz, 1H), 6.89 (d, J = 7.6 Hz, 1H), 6.96 (m, 2H), 7.05 (t, J = 7.9 Hz, 1H), 7.10 - 7.17 (m, 2H).

[0227] LCMS (Method: Atlantis T3 column, 2.1 x 50 mm, 3 μm, 5 to 95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, Flow rate: 0.7 mL / min, Wavelength: 210 nm): Retention time: 4.5 min, 99.9% purity, (EI-MS): m / z = 383.3 ([M+H] + )

[0228] Chiral HPLC (Chiralpak IG column, 250 mm × 4.6 mm, 5 μm, method: 100% EtOH, flow rate: 0.3 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 16.6 min, (S) isomer: 21.2 min, 99.9% ee. Example 8 Synthesis of (R)-(2,3-dimethoxyphenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (Compound 215) Scheme 16. Preparation of (R)-(2,3-dimethoxyphenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (compound 215). [ka]

[0229] Step 1. (2,3-dimethoxyphenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (7i). A solution of 9b (0.16 g, 0.80 mmol) in DMF (3 mL) followed by sodium bicarbonate (0.13 g, 1.6 mmol) was added to a solution of 30b (0.21 g, 0.80 mmol) in DMF (7 mL) at room temperature. The reaction mixture was heated at 90 °C for 2.5 h, cooled to room temperature, and concentrated under reduced pressure. The residue was diluted with water (10 mL) and extracted with EtOAc (3 x 25 mL). The combined organic layers were washed with saturated brine (20 mL), dried (Na2SO4), filtered and concentrated under reduced pressure to give crude 7i (0.26 g, 87% yield) as a clear oil that solidified upon standing.

[0230] Chiral separation of (R)-(2,3-dimethoxyphenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (compound 215). 7i (266 mg) was purified by chiral SFC (AD-H, 250×20 mm, 5 mm, 20% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 60 mL / min, wavelength 220 nm) to give the early eluting (R) enantiomer as a clear oil (134 mg).

[0231] The resulting clear oil was triturated with CH2Cl2 and hexanes to give compound 215 (105 mg) as a white solid.

[0232] 1 H NMR (400 MHz, CDCl3) δ 2.29 (br s, 1H), 2.74 (s, 2H), 3.87 (s, 6H), 4.63 (s, 1H), 6.85 (dd, J = 1.5, 8.1 Hz, 1H), 6.89 (dd, J = 1.2, 7.8 Hz, 1H), 6.95 (t, J = 8.7 Hz, 2H), 7.05 (t, J = 7.9 Hz, 1H), 7.10 - 7.18 (m, 2H).

[0233] LCMS (Method: Atlantis T3 column, 2.1 x 50 mm, 3 μm, 5 to 95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, Flow rate: 0.7 mL / min, Wavelength: 210 nm): Retention time: 4.6 min, 99.8% purity, (EI-MS): m / z = 385.3 ([M+H] + )

[0234] Chiral HPLC (Chiralpak IG column, 250 mm x 4.6 mm, 5 μm, method: 100% EtOH, flow rate: 0.3 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 16.8 min, (S) isomer: 21.3 min, 99.2%ee Example 9 Synthesis of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (Compound 347) Scheme 17. Preparation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (compound 347). [ka]

[0235] Step 1. tert-Butyl 4-(2,3-bis(methoxy-d3)benzoyl)piperidine-1-carboxylate-2,2,3,3,4,5,5,6,6-d9 (4d). A solution of 2.5 M n-butyllithium in hexanes (2.89 mL, 7.23 mmol) was added dropwise to a solution of 21b (0.99 g, 6.90 mmol) in anhydrous THF (16 mL) at 0 °C. After the addition, the reaction mixture was warmed to room temperature, stirred for 2 h, and then recooled to 0 °C. A pre-cooled (0 °C) solution of 2b (1.94 g, 6.90 mmol) in THF (14 mL) was added slowly to the reaction mixture. The reaction mixture was warmed to room temperature and then stirred overnight. An additional portion of 21b (0.99 g, 6.9 mmol) in anhydrous THF (16 mL) was treated with 2.5 M n-BuLi in hexanes (2.89 mL, 7.23 mmol) at 0° C. and then added to the reaction mixture at 0° C. The reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with saturated ammonium chloride solution in deuterium oxide (35 mL, CIL, 99.9% D atom) and stirred for 15 min. The layers were separated and the aqueous layer was extracted with EtOAc (3×100 mL). The combined organic layers were washed with saturated brine in deuterium oxide (60 mL, CIL, 99.9% D atom), dried (Na2SO4), filtered and concentrated under reduced pressure to give crude 4d (3.9 g) as a yellow oil. The crude material was purified by chromatography (Biotage automated chromatography). The product was then repurified by reverse phase chromatography (Biotage automated chromatography system, Teledyne 100g C60 silica gel cartridge, eluting with a gradient of 10-15% EtOAc in hexanes). 18 Cartridge, eluting with a gradient of 0–85% acetonitrile in water) to give 4d (1.16 g, 46% yield) with 19% proton incorporation alpha to the ketone group.

[0236] Potassium carbonate (0.66 g, 4.77 mmol) was added to a solution of 4d (1.16 g, 3.18 mmol) thus obtained in a 1:1 mixture of deuterium oxide (100 mL, CIL, 99.9% D atom) and anhydrous THF (100 mL) at rt. The reaction mixture was stirred for 3 days. The reaction mixture was partitioned between saturated brine in deuterium oxide (60 mL, CIL, 99.9% D atom) and CHCl (300 mL). The layers were separated and the aqueous layer was extracted with CHCl (200 mL). The combined organic layers were washed with saturated brine in deuterium oxide (100 mL, CIL, 99.9% D atom), dried (NaSO), filtered and concentrated under reduced pressure to give 4d (1.18 g) as a clear oil.

[0237] Step 2. (2,3-bis(methoxy-d3)phenyl)(piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanone trifluoroacetate (5d). Trifluoroacetic acid-d (10.88 g, 95.5 mmol, Sigma Aldrich, 99.5% D atom) was added neat to 4d (1.16 g, 3.2 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 3 h. The reaction mixture was concentrated under reduced pressure to give a yellow oil. Et2O (100 mL) was added to the residue. The mixture was stirred for 10 min, resulting in the formation of a heavy white precipitate. The solid was filtered to give 5d (1.17 g, quantitative yield) as a white solid.

[0238] Step 3. (2,3-bis(methoxy-d3)phenyl)(piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (30c). Sodium borohydride (0.49 g, 12.9 mmol) was added in one portion to a solution of 5d (1.17 g, 3.22 mmol) in MeOD (60 mL, Sigma Aldrich, 99.5% D atom) at 0 °C. The reaction mixture was warmed to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between saturated sodium bicarbonate solution in deuterium oxide (50 mL, CIL, 99.9% D atom) and CHCl (100 mL). The layers were separated and the aqueous layer was extracted with CHCl (2 x 100 mL). The combined organic layers were washed with deuterium oxide (50 mL, CIL, 99.9% D atom), dried (Na2SO4), filtered, and concentrated under reduced pressure to give 30c (0.26 g). The combined aqueous layers were concentrated under reduced pressure, and the residue was extracted with CH2Cl2 (3 x 100 mL). The combined organic extracts were concentrated under reduced pressure to give 30c (0.74 g, 87%).

[0239] Step 4. (2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (7k). A solution of 9a (0.18 g, 0.90 mmol) in DMF (3 mL) followed by powdered sodium bicarbonate (0.15 g, 1.8 mmol) was added to a solution of 30c (0.24 g, 0.90 mmol) in DMF (7 mL) at room temperature. The reaction mixture was heated at 90° C. for 2.5 h, cooled to rt, and concentrated under reduced pressure. The residue was diluted with water (10 mL) and extracted with EtOAc (3×25 mL). The combined organic layers were washed with saturated brine (20 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure to give crude 7k (0.31 g, 88%) as a clear oil that became a solid upon standing.

[0240] Chiral separation: (R)-(2,3-bis(methoxy-d3)phenyl)(1-(4-fluorophenethyl)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9) Methanol (compound 347). 7k (290 mg) was purified by chiral SFC (AD-H, 250×20 mm, 5 mm, 20% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 60 mL / min, wavelength 220 nm) to give the early eluting (R) enantiomer (154 mg) as a clear oil.

[0241] The resulting clear oil was triturated with CH2Cl2 and hexanes to give compound 347 (102 mg) as a white solid.

[0242] 1 H NMR (400 MHz, CDCL3) δ 2.32 (br s, 1H), 2.51 (d, J = 16.5 Hz, 2H), 2.75 (d, J = 16.5 Hz, 2H), 4.63 (s, 1H), 6.84 (d, J = 6.9 Hz, 1H), 6.89 (d, J = 7.5 Hz, 1H), 6.95 (t, J = 8.7 Hz, 2H), 7.04 (t, J = 7.9 Hz, 1H), 7.10 - 7.18 (m, 2H).

[0243] LCMS (Method: Atlantis T3 column, 2.1 × 50 mm, 3 μm, 5–95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, Flow rate: 0.7 mL / min, Wavelength: 210 nm): Retention time 4.6 min, 99.8% purity, (EI-MS): m / z = 389.3 ([M+H] + )

[0244] Chiral HPLC (Chiralpak IG column, 250 mm × 4.6 mm, 5 μm, method: 100% EtOH, flow rate: 0.3 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 16.9 min, (S) isomer: 21.4 min, 99.3% ee. Example 10 Synthesis of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (Compound 359) Scheme 18. Preparation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (compound 359). [ka]

[0245] Step 1. (2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (7 m). A solution of 9b (0.19 g, 0.90 mmol) in DMF (3 mL) followed by sodium bicarbonate powder (0.15 g, 1.8 mmol) was added to a solution of 30c (0.24 g, 0.90 mmol) in DMF (7 mL) at room temperature. Reaction The mixture was heated at 90° C. for 2.5 h, cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (10 mL) and extracted with EtOAc (3×25 mL). The combined organic layers were washed with saturated brine (20 mL), dried (Na2SO4), filtered and concentrated under reduced pressure to give 7m (0.30 g, 83%) as a clear oil that solidified on standing.

[0246] Chiral separation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1-d2)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (compound 359). 7m (289 mg) was purified by chiral SFC (AD-H, 250×20 mm, 5 mm, 20% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 60 mL / min, wavelength 220 nm) to give the early eluting (R) enantiomer as a clear oil (148 mg). The resulting clear oil was triturated with CHCl2 and hexane to give compound 359 (113 mg) as a white solid.

[0247] 1H NMR (400 MHz, CDCl3) δ 2.32 (br s, 1H), 2.74 (s, 2H), 4.63 (s, 1H), 6.84 (d, J = 8.1 Hz, 1H), 6.89 (d, J = 7.8 Hz, 1H), 6.95 (t, J = 8.7 Hz, 2H), 7.04 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 13.9 Hz, 2H).

[0248] LCMS (Method: Atlantis T3 column, 2.1 × 50 mm, 3 μm, 5–95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, flow rate: 0.7 mL / min, wavelength: 210 nm): 4.5 min, 99.8% purity, (EI-MS): m / z = 391.3 ([M+H] + )

[0249] Chiral HPLC (Chiralpak IG column, 250 mm × 4.6 mm, 3 μm, method: 100% EtOH, flow rate: 0.3 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 16.8 min, (S) isomer: 21.4 min, 99.2% ee. Example 11 Synthesis of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1,2,2-d4)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (Compound 383) Scheme 19. Preparation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1,2,2-d4)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (compound 383) [ka]

[0250] Step 1. (2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1,2,2-d4)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (7n). To a solution of 30c (0.27 g, 1.0 mmol) in DMF (7 mL) was added NaHCO3 (0.17 g, 2.0 mmol) followed by a solution of 9c (0.21 g, 1.0 mmol) in DMF (3 mL). The reaction mixture was heated at 90 °C for 2.5 h, cooled to room temperature, and concentrated under reduced pressure. The residue was diluted with water (10 mL) and extracted with EtOAc (3 x 25 mL). The combined organic layers were washed with saturated brine (20 mL), dried (Na2SO4), filtered and concentrated under reduced pressure to afford 7n (0.35 g, 90%) as a clear oil that solidified upon standing.

[0251] Chiral separation of (R)-(2,3-bis(methoxy-d3)phenyl)(1-(2-(4-fluorophenyl)ethyl-1,1,2,2-d4)piperidin-4-yl-2,2,3,3,4,5,5,6,6-d9)methanol (compound 383). 7n (350 mg) was purified by chiral SFC (AD-H, 250 x 20 mm, 5 mm, 20% EtOH (0.1% diethylamine / CO2, 100 bar, flow rate 60 mL / min, wavelength 220 nm) to give the early eluting (R) enantiomer as a clear oil (150 mg).

[0252] The resulting clear oil was triturated with CH2Cl2 and hexanes to give compound 359 (142 mg) as a white solid.

[0253] 1 H NMR (400 MHz, CDCl3) δ 2.32 (s, 1H), 4.63 (s, 1H), 6.84 (d, J = 8.1 Hz, 1H), 6.89 (d, J = 7.8 Hz, 1H), 6.95 (t, J = 8.8 Hz, 2H), 7.04 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 14.1 Hz, 2H).

[0254] LCMS (Method: Atlantis T3 column, 2.1 x 50 mm, 3 μm, 5 to 95% acetonitrile / water with 0.1% formic acid in 14 min, 4 min hold, Flow rate: 0.7 mL / min, Wavelength: 210 nm): Retention time: 4.5 min, 99.9% purity, (EI-MS): m / z = 393.3 ([M+H] + )

[0255] Chiral HPLC (Chiralpak IG column, 250 mm × 4.6 mm, 5 μm, method: 100% EtOH, flow rate: 0.3 mL / min, wavelength: 230 nm): Retention time: (R) isomer: 16.8 min, (S) isomer: 21.4 min, 99.3% ee. Example 12 Assessment of metabolic stability in human liver microsomes

[0256] Microsomal Assay: Human liver microsomes (20 mg / mL) were obtained from Xenotech, LLC (Lenexa, KS). The reduced form of β-nicotinamide adenine dinucleotide phosphate (NADPH), magnesium chloride (MgCl2), and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich.

[0257] Determination of metabolic stability: A 7.5 mM stock solution of a test compound of structural formula (I) (e.g., of an embodiment or aspect of an embodiment thereof described herein) or structural formula (II), or a pharma- ceutically acceptable salt thereof, was prepared in DMSO. The 7.5 mM stock solution was diluted to 12.5-50 μM with acetonitrile (ACN). Human liver microsomes at 20 mg / mL were diluted to 0.625 mg / mL with 0.1 M potassium phosphate buffer, pH 7.4, containing 3 mM MgCl2. The diluted microsomes were added in triplicate to wells of a 96-well deep well polypropylene plate. A 10 μL aliquot of the test compound at 12.5-50 μM was added to the microsomes, and the mixture was allowed to sit for 10 min in the pre-incubated 5% CO2 solution. The reaction was started by adding pre-warmed NADPH solution. The final reaction volume was 0.5 mL and contained 4.0 mg / mL human liver microsomes, 0.25 μM test compound, and 2 mM NADPH in 0.1 M potassium phosphate buffer, pH 7.4, and 3 mM MgCl2. The reaction mixture was incubated at 37° C., and 50 μL aliquots were removed at 0, 5, 10, 20, and 30 minutes and 50 μL ice-cold ACN (acetonitrile) was added to a shallow well 96-well plate containing internal standards to stop the reaction. The plate was stored at 4° C. for 20 minutes, after which 100 μL water was added to the wells of the plate, followed by centrifugation to pellet precipitated proteins. The supernatant was transferred to another 96-well plate and analyzed for the amount of remaining parent by LC-MS / MS using an Applied Bio-systems API 4000 mass spectrometer. The same procedure was carried out for the non-deuterated counterpart of the compound of formula I and the positive control 7-ethoxycoumarin (1 μM). Tests were performed in triplicate.

[0258] Data analysis: In vitro t 1 / 2 was calculated from the slope of the linear regression (ln) of % parent remaining versus incubation time. In vitro 1 / 2 =0.693 / k k = -[slope of linear regression (ln) of % parent remaining versus incubation time] The apparent intrinsic clearance was calculated using the following equation: CL int (mL / min / kg) = (0.693 / in vitro t 1 / 2 )(incubation volume / mg microsomes)(45mg microsomes / gram liver)(20g liver / kg bw)

[0259] Data analysis was performed using Microsoft Excel software, and the results are shown in Tables 5 and 6 below. [Table 5] [Table 6]

[0260] In these experiments, increases equal to or exceeding 15% of the half-life are considered significant. Apparent intrinsic clearance ratios (deuterated compound / borinancerin) of >1.15 or <0.85 are considered significant.

[0261] The results showed that deuterated compounds 147, 115, 148, 131, 151, 159, 359, and 383 had significantly longer half-lives (t 1 / 2 ), whereas deuterated compounds 203, 215, and 347 did not. (Example 13) Assessment of metabolic stability in CYP3A4 Supersomes material and method

[0262] Materials: CYP3A4 supersomes® were obtained from Corning Gentest. β-Nicotinamide adenine dinucleotide phosphate reduced form (NADPH), magnesium chloride (MgCl2), and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich. D-Crizotinib compound was supplied by Concert Pharmaceuticals.

[0263] Determination of metabolic stability: 10 mM stock solutions of test compounds were prepared in DMSO. 7.5 mM stock solutions were diluted to 12.75 μM in acetonitrile (ACN). CYP3A4 supersomes were diluted to 50 pmol / mL in 0.1 M potassium phosphate buffer, pH 7.4, containing 3 mM MgCl2. The diluted supersomes were added in triplicate to wells of a 96-well deep-well polypropylene plate. 10 μL of 12.75 μM test compound was added to the supersomes and the mixture was pre-warmed for 10 min. The reaction was started by adding pre-warmed NADPH solution. The final reaction volume was 0.5 mL and contained 50 pmol / mL CYP3A4 supersomes, 0.25 μM test compound, and 2 mM NADPH in 0.1 M potassium phosphate buffer, pH 7.4, and 3 mM MgCl2. The reaction mixture was incubated at 37° C. and 50 μL aliquots were removed at 0, 5, 10, 20, and 30 min and transferred to shallow wells containing 50 μL ice-cold ACN along with the internal standard. The reaction was stopped by adding 100 μL of water to the wells of a 96-well plate. The plate was stored at 4° C. for 20 min, after which 100 μL of water was added to the wells of the plate and then centrifuged to pellet the precipitated proteins. The supernatant was transferred to another 96-well plate and analyzed for the amount of remaining parent by LC-MS / MS using an Applied Bio-systems API 4000 mass spectrometer.

[0264] Data analysis: In vitro t 1 / 2 was calculated from the slope of the linear regression (ln) of % parent remaining versus incubation time. In vitro 1 / 2 =0.693 / k k = -[slope of linear regression (ln) of % parent remaining versus incubation time]

[0265] Data analysis was performed using Microsoft Excel software, and the results are shown in Tables 7 and 8 below. [Table 7] [Table 8]

[0266] In these experiments, an increase equal to or greater than 15% of the half-life was considered to be a significant difference. The results showed that deuterated compounds 147, 115, 148, 131, 151, 159, 347, 359, and 383 significantly increased the half-life (t 1 / 2 ), whereas deuterated compounds 203 and 215 did not.

[0267] The relevant teachings of all patents, published patent applications and references cited herein are incorporated by reference in their entirety.

[0268] It is believed that those skilled in the art can use the above description and illustrative examples to make and utilize the compounds of the present invention and to carry out the claimed methods without further explanation. It should be understood that the above discussion and examples merely provide a detailed description of certain preferred embodiments. It will be apparent to those skilled in the art that various modifications and equivalents can be made without departing from the spirit and scope of the present invention. In one embodiment, for example, the following items are provided: (Item 1) Compounds represented by structural formula (I) [ka] or a pharma- ceutically acceptable salt thereof, R 1 and R 2 is independently selected from -CH3, -CH2D, -CHD2, and -CD3; X is -OH or -F, and Y 1a , Y 1b, Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each independently selected from hydrogen and deuterium; However, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 At least one of the following is a deuterium atom: However, Y 1a , Y 1b , Y 2a , and Y 2b are deuterium, Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 at least one of contains deuterium, and However, Y 3a , Y 3b , Y 4a , and Y 4b are deuterium, Y 1a , Y 1b , Y 2a , Y 2b , Y 5 , Y6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 At least one of the following is a deuterium atom: Each position specifically designated as deuterium has at least 50.1% deuterium incorporation]. (Item 2) R 1 and R 2 is independently selected from -CH3 and -CD3. (Item 3) The compound according to any one of the preceding items, wherein X is -OH. (Item 4) Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 and each is hydrogen. (Item 5) Y 4a and Y 4b are the same. (Item 6) Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 and each is hydrogen. (Item 7) Y 1a and Y 1b are the same. (Item 8) Y 2a and Y 2b are the same. (Item 9) Y 3a and Y3b are the same. (Item 10) R 1 and R 2 is independently selected from -CH3 and -CD3, X is -OH, and Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a , Y 1b , Y 2a and Y 2b is the same, and Y 3a and Y 3b are the same. (Item 11) R 1 and R 2 is independently selected from -CH3 and -CD3, X is -OH, and Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are hydrogen, and Y 1a and Y 1b is the same, and Y 2a , Y 2b , Y 3a and Y 3b are the same. (Item 12) Y 2a and Y 2b is deuterium. (Item 13) The compound of any one of the preceding items, wherein any atom not designated as deuterium is present at its natural isotopic abundance. (Item 14) X is -OH and Y 1a and Y1b But it is the same, Y 2a and Y 2b But it is the same, Y 3a and Y 3b is the same, and Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each hydrogen, and the compound is any one of the compounds set forth in Table 1 below. [Table 1-3] [Table 1-4] [Table 1-5] or a pharma- ceutically acceptable salt of any of the foregoing, wherein any atom not designated as deuterium is present at its natural isotopic abundance. (Item 15) X is -OH and Y 1a and Y 1b But it is the same, Y 2a and Y 2b But it is the same, Y 3a and Y 3b is the same, and Y 4a , Y 4b , Y 5 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each hydrogen, and the compound is any one of the compounds listed in Table 2 below. [Table 2-3] or a pharma- ceutically acceptable salt of any of the foregoing, wherein any atom not designated as deuterium is present at its natural isotopic abundance. (Item 16) X is -OH and Y 1a and Y 1b But it is the same, Y 2a and Y 2b But it is the same, Y 3a and Y 3b But it is the same, Y 4a and Y 4b is the same, and Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each hydrogen, and The compound is any one of the compounds listed in Table 3 below. [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] or a pharma- ceutically acceptable salt of any of the foregoing, wherein any atom not designated as deuterium is present at its natural isotopic abundance. (Item 17) X is -OH and Y 1a and Y 1b But it is the same, Y 2a and Y 2b But it is the same, Y 3a and Y 3b But it is the same, Y 4a and Y 4bis the same, and Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each hydrogen, and the compound is any one of the compounds set forth in Table 4 below. [Table 4-3] or a pharma- ceutically acceptable salt of any of the foregoing, wherein any atom not designated as deuterium is present at its natural isotopic abundance. (Item 18) The compound of any one of the preceding claims, wherein each position specifically designated as deuterium has at least 90% deuterium incorporation. (Item 19) The compound of any one of the preceding claims, wherein each position specifically designated as deuterium has at least 95% deuterium incorporation. (Item 20) The compound of any one of the preceding claims, wherein each position specifically designated as deuterium has at least 97% deuterium incorporation. (Item 21) Compounds represented by structural formula (I) [ka] or a pharma- ceutically acceptable salt thereof, R 1 and R 2 is independently selected from -CH3, -CH2D, -CHD2, and -CD3; X is -OH or -F, and Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y7 , Y 8 , Y 9 , Y 10 , and Y 11 are each independently selected from hydrogen and deuterium; However, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 at least one of which contains deuterium; or A compound according to any one of items 1 to 15, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier. 13. A pharmaceutical composition comprising: (Item 22) A method for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, dementia with Lewy bodies, sleep disorder, agitation, mood disorder, thromboembolic disorder, autism, attention deficit hyperactivity disorder, and any combination thereof in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by structural formula (I): [ka] or a pharma- ceutically acceptable salt thereof, R 1 and R 2 is independently selected from -CH3, -CH2D, -CHD2, and -CD3; X is -OH or -F, and Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a, Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each independently selected from hydrogen and deuterium; However, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 at least one of which contains deuterium; A method comprising administering a compound according to any one of items 1 to 15 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to item 17. (Item 23) 23. The method of claim 22, wherein the subject is a human. (Item 24) A pharmaceutical composition for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, dementia with Lewy bodies, sleep disorder, agitation, mood disorder, thromboembolic disorder, autism, attention deficit hyperactivity disorder, and any combination thereof, comprising a compound represented by structural formula (I): [ka] or a pharma- ceutically acceptable salt thereof, R 1 and R 2 is independently selected from -CH3, -CH2D, -CHD2, and -CD3; X is -OH or -F, and Y 1a , Y 1b , Y2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each independently selected from hydrogen and deuterium; However, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 at least one of which contains deuterium], or a pharmaceutical composition comprising a compound according to any one of items 1 to 15. (Item 25) A compound represented by structural formula (I) for use in the treatment or prevention of a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, dementia with Lewy bodies, sleep disorders, agitation, mood disorders, thromboembolic disorders, autism, attention deficit hyperactivity disorder, and any combination thereof. [ka] or a pharma- ceutically acceptable salt thereof, R 1 and R 2 is independently selected from -CH3, -CH2D, -CHD2, and -CD3; X is -OH or -F, and Y 1a , Y 1b , Y 2a , Y 2b , Y3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each independently selected from hydrogen and deuterium; However, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 at least one of which contains deuterium; Or the compound according to any one of items 1 to 15, or a pharma- ceutically acceptable salt thereof. (Item 26) A compound represented by structural formula (I) for the manufacture of a medicament for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, dementia with Lewy bodies, sleep disorder, agitation, mood disorder, thromboembolic disorder, autism, attention deficit hyperactivity disorder, and any combination thereof. [ka] or a pharma- ceutically acceptable salt thereof, R 1 and R 2 is independently selected from -CH3, -CH2D, -CHD2, and -CD3; X is -OH or -F, and Y 1a , Y 1b , Y 2a , Y 2b , Y3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , and Y 11 are each independently selected from hydrogen and deuterium; However, Y 1a , Y 1b , Y 2a , Y 2b , Y 3a , Y 3b , Y 4a , Y 4b , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , R 1 and R 2 at least one of which contains deuterium; or Use of the compound according to any one of items 1 to 15 or a pharma- ceutically acceptable salt thereof.

Claims

[Claim 1] The invention described in the specification.